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INTRODUCTION 
In recent years a large number of pept:ides, many of which were 
originall.y characterized in non-neural. tissues, have been reported to be 
present in the central nervous system ( CNS) . The detection of these 
peptides within the CNS has raised many questions regard~g their source 
and mechanism of acti.on. 
In view of the accumulating information, it seems that the function of the 
classical neurotransmitters in the CNS would be better clarified by 
elucidating the role of the brain neuropeptides. 
The classification of the major categories of the main peptides, as listed 
below, i.s a some what arbitrary one as it is based on the first 
localization of a given peptide, while the opioid peptide family is given 
separatel.y. Por many of the pepti.des described in brain, their major 
functional role is still unknown. However, even before the major 
discoveries in the past decade, the opiates were known to possess selective 
and unique pharmacological properties. It was well known that opiates were 
effective ~ the treatment of pain and were useful as cough suppressants. 
They are also known to depress respiration and blood pressure and to exert 
an effect on behaviour, like euphoria, sedation and depression. The 
diversity/complexity of their properties suggests that like the 
catecholam.ines, endogenous opioid.s may have a basic, multisystem regulation 
essential to the maintenance of homeostasis and to the survival of the 
organism. 
In the last years we have tried to reveal one of these pe~idergi.c secrets 
and focussed our attention on the opioid pe~ides, more specifically in 
relation to the excitatory phenomena which they might induce after systemic 
or intraventricular administration. 
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categories of mammalian brain oeptides 
.. Bypot.ha~am'£.c-re~east.ng hormones•• 
Thyrotropin-releasing hormones 
Gonadotropin-releasing ho~nes 
Somatostatin 
corticotropin-releasing hormones 
Growth hormone-releasing hormone 
NeurohypophyseaL hormones 
vasopressin 
Oxytocin 
Neurophysin 
~~ut.~ary pept.t.des 
Adrenocorticotropic hormone 
cx-Melanocyt-stimul.ati.ng hormone 
Prolactin 
Luteinizing hormone 
Growth hormone 
Thyrotropin 
Invert.e~rat.e peptt.des 
Pheny1alanyl. methi.onyl. argi.ninyJ. phenylalanylam.ide ( FMRF amide) 
Hydra head activator 
Gastrot.ntestt.naz. peptt.des 
Vasoactive intestinal. polypeptide 
Cholecystokinin 
Gastrin 
SUbstance P 
Neurotensin 
Insulin 
Glucagon 
Bombesin 
secretin 
Somatostatin 
Moti.l.in 
O-thers 
Angiotensin II 
Bradykinin 
Carnos:ine 
S1eep peptide(s) 
Cal.citocin 
Neuropeptide Yy 
Op~t.d peptt.de f~Z.y 
Leu-enkephalin 
Met-enkephalin 
a.-endorphin 
trendorphin 
y-endorphin 
Dynorphin 
Peptide E 
a-neoendorphin 
,e-neoendorphin 
CHAPTER I. 
OPLOID PEPTCDES 
1. NOMENCLATURE 
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The term "opioid peptides .. has usually been appl.i.ed to "naturaU.y occuri.ng 
pept:ides wi.th opiate-like bi.ol.ogicaJ. properties" (Morley 1983). The 
various members of the fami.ly of the opioid pepti.des ( for structural 
formulae of some agents, see Table 1.) can be divided into five main groups: 
1.1. The enkephaL~ns 
'they usually :i.ncl.ude two naturally occurring pentapeptides, 
methionine-enkephali.n and leucine-enkephali.n (Hughes et al., 1975). 
In this manuscript the term ''enkephali.n" refers to these compounds but 
will also embrace synthetic enkephalin analogues like: 
( D-ala 2 , D-leu 5 )enkephal.i.n ( DADL), ( D-al.a 2 , L-met 5 )enkephal.i.n ( DAIA) and 
(D-ser2 ,L-r.eu5 )enkephalyl-thr (DSTLE ). 
1..2. The endorph~ns 
These refer to 13-endorphi.n (Bradbury et al.., 1976; Li and Chung, 
1.976) and the related a.-, y- and s-endorphins (Ling et al., 1976; 
Verhoef et al., 1980). It should be noted that the term "endorphin" 
(endogenous morphine-bke substances) and "opioid peptide" have often 
been used synonymously. To avoid confusion~ a more restricted 
definition of endorphin, i.e. those opioid peptides that ari.Se from 
{3-lipotropi.n, has lately been recommended (Morley, 1.983). In this 
manuscript the terms "endorphin" and "endorphinergic", unless stated 
otherwise, are used as a general reference to all opioid peptides. 
1..3. Pept~aes that ar~se or are presumea ~ ar~se, from 
enkephaL~n-precursors. 
This category includes three peptides arising from adrenal 
proenkephalin (Rossier et al., 1.980), peptide E (Kilpatrick et 
aL, 1981 ), dynorphin (Goldstein et al., 1981.) and 
,(3-neoendorphi.n (Kangawa et al., 1981.; Mi.namino et al.., 1.981.). 
1.4. Pronase res~stant pept~aes ~n body fLu~as. 
ex- and 
{3-casomorphin-5 and -7 in bovine milk (Henschen et al., 1979) and 
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anodynin in blood (Pert et al. I 1976) are included in this category. 
~.5. ~sce~Laneous pe~~aes ~hose op~a~e-L~ke propert~es ao not ar~se from 
a a~re~ ~n~ract~n ~~th o~ate or opiate-Ltke receptors. 
An example l.s kyotorph:in which seems to act via release of 
enkepbal.i.ns and inhibition of enkephali.n degradation (Takagi et 
al.. , 1979 ) • 
In this manuscript we will deal mainly with the pharmacological/ 
electrophysiological properties of the first two groups, i.e. the 
enkephalins and endorphins. 
TabLe 1. STRIJCI'URES OF OPIOID PEPTIDES 
(Leu )enkephal.in 
(Met )enkephal.i.n 
(Met)enkepbal.inyl-Arg-Phe 
(Met)enkephali.n-8 
Peptide E 
Dynorphin A ( 1-17) 
Dynorphin A ( 1. -s ) 
Dynorphin B (l-13) 
a-Neoendorphin 
,6-Neoendorphin 
PH-SP 
13-Endorphi.n 
a-Endorphin 
y-Endorphi.n 
S-Endorphin 
.e--casomorphin-7 
.e--casomorph:i..n-5 
Kyotorphi.n 
Tyr-G~y--Gly-Phe-Leu 
Tyr-Gly--Gly-Phe-Met 
Tyr-Gly--Gly-Phe-Met-Arg-Phe 
Tyr-Gly--Gly-Phe-Met-Arg-Gly-Leu 
Tyr-Gly--Gly-Phe-Met-Arg-Arg-val.-Gly-Arg-Pro-
1 5 w 
Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-
1.5 20 
Gly-Phe-Leu 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-
1. 5 10 
Leu-Lys-Trp-Asp-1\sn-Gln 
15 17 
1-s sequence 
l-13 sequence 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys 
Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro 
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile 
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-ser-Gln-
1 5 w 
Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-A1a-Ile-
15 20 
Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu 
25 30 31 
1-16 sequence 
1-17 sequence 
J.-27 sequence 
Tyr-Pro-Phe-Pro-Gly-Pro-Ile 
Tyr-Pro-Phe-Pro-Gly 
Tyr-Arg 
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2. BIOGENESIS AND DEGRADATION OF THE OPIOIO PEPTIDES 
The different classes of the opioid peptides the 
endorphins and the dynorphins may function as 
neuromodulators or ho~nes. The receptor-mediated 
enkephalins, the 
neurotransmitters, 
actions of these 
opioids show a considerable overLap, not surpris1ngly in view of their 
close structural relationships (Table 1.). 'rhus in order to understand the 
roles of these peptides in physiological or pathological events, it is 
necessary to elucidate the mechanisms underlying and controlling their 
biogenesis, inactivation and release. 
2.1.. ~osyn~hes~s 
Peptide hormones are derived from the enzymatic cleavage o£ Larger, 
and generally inactive prohormones which are synthesized under the 
direction of mRNA on membrane-bound pol.yrihosomes. The nascent 
protein characteristically contains a 1.8-25 residue hydrophobic amino 
acid sequence at its N-termi.nus, termed the "signal sequence••. The 
cleavage of this pre-prohormone in its entry into the Golgi apparatus 
yields the prohormone. Sequential cleavage of the prohormone then 
results in one or more biologically active peptides that are available 
for secretion ( Mal:x, 1983). 
The use of modern techniques, including ~ cloning, has revealed the 
total sequences of the following prohormones: 
L Proopiomelanocortin (POMC) (Smyth, 1983); 2. Proenkephalin (Noda 
et al., 1982 ); 3. Prodynorphi.n (Kak.idani et al., 1982). These 
proteins provide the basis for three separate opioid peptide families. 
2.1.1. Proopiomelanocortin (POMC) 
POMC was the first of the precursors to be identified. The sequence 
of amino acids in the complete POMC molecule results after cleavage 
in at least seven active peptides including 13-lipotropi.n (13-LPH), 
,6-endorphin, adrenocorticotropic hormone (ACTII), and a-, {!r-, and 
y-melanocyte stimulating hormones (a-, (3-, and y-MSEI) (Pig. la) 
( Ma:rx, 1983). The individual pepti.des in the precursor are bound on 
both ends by pairs of amino acid residues, usually containing one 
lysine and one arginine residue. These pairs are the sites, 
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recognized and cut by the protei.n-spl:itting enzymes (this chapter), 
that release the active opioids. 
A1though Met-erikephalin is the 61-65 sequence of ~ndorphin, i.t is 
very unlikely that Met-enkephal.in is formed in the brain by 
degradation of c-endorphin (watson et al., 1.977). 
The major places of synthesis of POMC a:re the intermediate and 
anterior lobes of the pi.tuitaxy, the bypothal.am:us as wel.l as some 
peripheral tissues including the placenta, gastrointestinal tract 
and lungs (Watson et al., 1.977). 
A: POMC 
y-MSH 
8: Pro-ENKEPHALIN 
II 
Signal NH 2 1 2 
~ \ .. ( 
C: Pro-DYNORPHlN 
Signal NH 2 
W/4'/AW@; 
8 met-enk. sequence 
~ leu-enk. sequence 
~y-LPH~ 
r-- ACTH -----,] 8-MSH I B-END COOH 
a-MSH 
3 
I IIIII I 
6-Neo-END 
'f;A II 
CUP B-LPH 
Leu-ENK 
I 
Met-ENK 
(Arg 6-Ph</) 
4 S 6 7 COOH 
II ,Ill li\11 II • 
Peptide E 
DYN A DYN 8 
1-8 1-13 14-29 COOH 
11*1 I IVil I • 
<:r-Neo-END 1-17 
Ftg.1. Schema~tc represen~a~ton of ~he precursor s~ruc~ures of ~he 
~hree optota pep~~ae fam~L~es (modified after Akil et al., 1984). 
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2 .1.. 2. Proerikephali.n A 
D~fferent groups of investigators (Noda et al. 1 1982; GUbler et 
al.., 1982) cloned the gene coding for the polypepti.de now cal.l.ed 
proenkephalin A. The proenkephal.in A and not POMC is the precursor 
of Met- and Leu-enkephalin and also of some larger 
enkephalin-containing pepti.des, some of them more active than the 
enkepbalins themselves (GUbler et al., 1982). 
Proenkephal:in A contai.ns six copi.es of the Met-enkephal.i.n sequence 
(Tyr-Gl.y-Gl.y-Phe-Met) and one of Leu-enkepha1in 
( Tyr-Gly-Gly-Phe-Leu) (Fig. 1.b). 
2 .1.. 3. Prodynorphin 
I<aki.dani et al. ( 1982) have identified a sequence from a DNA cl.one 
of porcine hypothalamic RNA which encodes the complete sequences of 
dynorphin and a-neoendorphin but which contains no Met-enkephalin 
sequence ( F:i.g. l.c) . Analysis of the DNA structure indicates that 
the precursor protein consists of 256 amino acids including a signal 
sequence. 
2.2. Me"taboZ.tsm 
The final products produced and stored within a given neuron depend 
not only on the genetic code for the precursor, but also on the 
program that directs the enzymes to process the precursor in certain 
ways. The action of cutting specific peptides out of the precursor 
protein, and modifying these products by acetylation, amidati.on, 
phosphorylation, methylation, glycosylati.on or further cleavage is 
part of the biological program of a given ceU.. 'l'hese events are 
capable of determining the exact mix of peptides in a given neuron. 
They appear to va:ry from one tissue to the next, in spite of the 
existence of a common gene for the precursor. Since these changes 
result in peptides of widely differing potencies, pharmacological 
profiles and receptor selectivities, they are critical in determining 
function and may constitute a critical step in the regulation and 
homeostasis of a given opi.oid system in a particular region in the 
CNS. 
Detailed studies on the biosynthesis of these pepti.des are lacking, 
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although in the last years some progress has been made in the nature 
of .. post-translational" proteolytic enzymes (Docherty and 
steiner, ~982; Lindberg et aL, 1982; Loh and Gainer, 1982 ). The 
variable processing of these multivalent prohormones would be a 
powerful adaptive mechanism. 
2.3. Re~ease of enkepha~~ns ana endbrph~ns. 
2.3.L stress- and pain associated release. 
There is a clear association between stressful conditions and the 
release of opioid peptides. Injury stress causes the parallel 
release via hypothalamic corticotropin releasing factor (CRF) of 
13-endorphi.n and corticotropin from the anterior pituitary ( Gui.llemin 
et al., 1977). various forms of conditioning and stress are 
associated with analgesic states, which are either partially or 
fully reversed by naloxone, an opiate antagonist (Madden et 
al., 1977; watkins et al., 1982). 
Interestingly, electroconvulsive theraPY", which can cause posti.ctal 
analgesia and catalepsy (Urea et aL, 1981), also results in 
:increased enkephali.n levels in hypothalamus and l.i.mbic brain areas 
(Hong et al.., 1979). No such changes were seen in ~endorphi.n 
l.evels. Selecti.ve brain st~lation also leads to analgesi.a and 
i.ncreased opioid peptide release into the cerebral spi.nal 
fluid (CSP) (Akil et al., 197Sa,b). 
Electroacupuncture and noxious stimuli result in increased opioid 
peptide levels, as well (SjOlund et al., 1977; cessel.in et 
al._ 1980). 
The mechani.sms underlying the release of opioid peptides during 
stressful. or painful. conditions still remain to be resolved. Opioid 
release may be diffuse and involve several different specifi.c 
neuronal. pathways. 
2.3.2. Steroid modulated release. 
steroids are the best known endogenous regulators of peptide hormone 
synthesi.s and release. The rel.ease and synthesis of 
adrenocorticotropic hormone/endorphin peptides is subject to 
corticosteroid feedback inhibition in the anterior pi.tuitary but not 
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in the intermediate l.obe (Bloom et al.., 1977). corticosterone acts 
to suppress both mRNA synthesis and CRF-modulated release. 
Factors controlling gonadotropin release might possibly be involved 
in op:io:id peptide release as welL oestrogen treatment reduces the 
13-endorphin levels in the hypothalamus, thalamus and mid-brain, 
while an increased ~ndorphin level was demonstrated during 
pregnancy ('Wardlaw et al.., 1982). 
2.3.3. Opioid peptide releasing agents. 
Some drug effects have been interpreted in terms of an :induction o£ 
opioid peptide rel.ease. For example, the analgesic properties of 
nitrous oxide (Berkowitz et al., 1977) and o£ intracerebrally 
injected substance P (stewart et al., 1976; Naranjo et al., 1982) 
are blocked or part:iall.y reversed by naloxone. It has a1so been 
suggested that the anaJ.gesic action of morphine may be due to 
endogenous opioid peptide release (Pu and Dewey, 1979; schlen and 
Bentley, 1980). 
Finally, certain inhibitors of the enkephalin breakdown will enhance 
enkephalin release and content. These effects are discussed below. 
2.4. Drug modu.Z.a'ted concen'tra'tt.on of enkephaZ.-tns and ena:orpht..ns. 
Reports of the effects on opiates have been contradictory. Acute 
morphine administration bas been claimed to increase ( Gros et 
al., 1978 ), or not to affect brain Met-enkephalin content (Wesche et 
al., 1977). Chronic morphine treatment apparently has no effect on 
brain enkephalin levels (Wesche et al., 1977) but decreases 
~endorphin content and synthesis in the anterior pituitary 
(PrzewloCki et al., 1979; HOllt et al., 1981). An opposite effect 
is seen with dynorphin. The pituitary level of this peptide is 
increased by chronic morphine treatment ( Herz et al. , 1982 ) . These 
effects of morphine may be mediated via stimulation of corticosteroid 
release (Hughes, 1983). 
2.5. Inac't~va't~n Of 'the opt..o~d pe~~des. 
Since the activity of the pept:ides depends on the rate of degradation, 
it has been of interest to determine what happens to them after they 
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have been released. Most research in this 'field has concerned 
enk.ephal.i.ns; which are extremely rapidly deqraded by enzymes in 
various tissue homogenates or in blood Hambrook et al., 1976; 
Dupont et al.., 1977). ,6--endorphin is cons:i.derably more stable (Miller 
et al.., 1.977). '!'his serves to expl.ai.n, at least partly, the greatly 
increased antinociceptive potency of ,6--endorphi.n over Met-enk.ephalin 
following intraventricular (ivt) :injection (Bel.l.uzzi et al., 1.976; 
Chang et al., 1976). 
A number of proteolytic enzymes are thought to be involved in the 
inactivation of enkephalin. This breakdown can occur at several sites 
of the peptide molecule as follows: 
1. The solUble am£nopepttdases degrade enk.ephalins at the 
Tyr 1-Gly 2 peptide bond. The hydrolysis product is tyrosine 
(Bambrook et al.., 1.976; Meek et al., 1977; Vogel and 
Altstein, 1.980). 
bestatin. 
The best inhibitor presently available is 
2. Dtpept;tdyl,-anri.nopept:t.aase ( "enkephalinase B") hydrolyses the 
Gly2-Gly3 amide bond of enkephalin. No selective inhibitor 
for this enzyme is available as yet ( Gorenstein and Snyder, 
1979). 
3. Angtot.enst.nwconvert.t,ng enzyme (ACE) hydrolyses the enkephalin 
3 4 
at the level o£ the Gly -Phe bond (Erdos et al., 1975). 
This enzyme can be inhibited by captopril. 
4. Df...pep"tt.dy1wcarbcxcypepti.dase termed "enkephaJ.inase" (Malfroy 
et al., J.97S) or "enkephal.i.nase A'' ( Gorenstei.n and Snyder 1 
l. 979 ) , which cleaves the enkephali.n al.so at the Gly 3 -Phe 4 
bond, can be inhibited by phosphoramidon or thiorphan. 
Recently, kelatorphan has been descr~ as the first complete 
inhibitor of enkephal.in metabolism. This substance inhibits the 
activity of ··enkephal.:inase A" 1 dipeptidylaminopeptidase and 
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aminopeptidase (Fournie-zaluski et al., 1994). 
Peptidases generally diSplay a limited chemical specificity. A given 
peptide can be hydrolyzed by different enzymes and a given peptidase 
can act on several opioid peptides. 
what extent these peptidases are 
This raises the question as to 
involved in the physiological 
degradation of the endogenous enkephal.i.ns. 
In homogenates of the guinea pig ileum ( GPI) or in the brain, 
enkephalin appears to be degraded mainly by removal. of the N-terminal 
tyrosine residue, although other minor modes of degradation might also 
exist ( Elambrook et aL, 1976). It iS therefore not surpriSing that 
enkephalin analogues, containing a D-amino acid in the second position 
instead of a glycine are considerably more stabl.e than the naturally 
occuri.ng enkephalins (Hambrook et al., 1976). 
The specificity or selectivity of the enzyme:{ s) remain( s) to be 
determi.ned, particularly since specifici:ty may be due to substrate 
specificity or anatomical location. The anatomical distribution, 
perhaps associated ~th l~ted substrate specificity, may well 
constitute a "functional" specificity. 
Attempts to find inhibitors of the different enzymes, trying to 
understand the degradation of the enkephali.ns, resulted in the 
synthesis of the different enkep~inase inhibitors. All 
enkephali.nase or aminopeptidase inhibitors tested so far enhance the 
analgesic potency of opi.oid pepti.des (Roques et al., l9BO; Chipkin et 
al., 1.982; Chaillet et aL, 1.983). The enkephalinase inhibitors 
thiorphan and phosphoramidon not only enhance the analgesic action of 
the opioids but have also analgesic properties when injected alone 
(Roques et al., 1.980; Rupreht et al., 1.983). These data indicate 
that enkephalinase inhibitors can potentiate an endogenous ongoinq 
enkephalinergic activity in the CNS, which resul.ts in the analgesic 
effect. 
Little is known about the endorph:in breakdown. .$-endorphin can be 
degraded by an enzyme in synaptosomal membranes (Austen et al., 1.977). 
The products formed depend on the p.EI at which the experiment is 
performed and also whether or not bacitracin, a breakdown inhibitor 
(Miller et al., 1.977) is present. Depending on the conditions 
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a-endorphin, y-endorphin or Ket-enk.ephalin can be formed. However, 
the nature of the various enzymes involved in these cleavages still 
has to be detel:llli.ned. 
Little is known about the metabolism or inactivation of dynorphin 
related pepti.des. 
It seems l.ik.ely that the main method of termination of action of 
opioid peptides in vivo will prove to be by degradation, as ~th 
acetylcholine, rather than by 
biogenic am.ines. At least, 
presynaptic 
peptidase 
reuptake, as with 
and enkephalinase A 
the 
are 
essential for the biodegradation of enkephalins, in vivo. 
3. CENTRAL DISTRIBtrl'ION OF THE OPIOID PEPTIDES 
several neurochemical. and immunochemical techniques, i.e. 
radioimmunoassay ( r. i. a. ) and immunohistochemistry, have been applied for 
the study of the distribution and cellular localization of opioids. Most 
studies tend to agree on the differential distribution of the opioids. 
'l'he major si.te of production of the peptides, derived from POMC, is the 
pituitary (Bloom et al., 1977; Pelletier et al., 1977). A small 
percentage of the anterior lobe cells produce ACTH, ~LPH and ~ndorphin. 
In most species, the pituitary conta:i.ns an intermediate lobe. All cells of 
this lObe produce ~ndorphinfACTH related pept:i.des, the main end points 
being .(3-endorphi.n and a:-MSH • The main cel.l group, producing 
.&-endorphin/ACTa rel.ated peptides, is found in the arcuate nucleus of the 
medial basal hypothalamus and projects its fibers very widely, including 
many areas of the limbic system and brain stem (Bloom et al., 1978; Watson 
and Akil, 1979,1980). 
The second major opioid neuronal pathway ( proenkephal.in A) is widespread 
and includes endocrine and CNS distributions (Elde et al.., 1976; HOkfelt 
et al., 1977; sar et al., 1978; watson, 1982). The concentration of 
Met-enkephalin is invariably found to be several fold greater than that of 
Leu-enkephalin (Yang et al., 1978; Goldstein and Ghazarossian, 1980). 
Possible explanations can be found in the fact that the precursor molecule 
for the enkephalins contains both peptides in a given proportion (see this 
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chapter). In brai.n.. pept'ides formed from pro-enkephal.i.n are found at every 
level of the neuraxis, including cells in the cortex all the way to cells 
in the spinal cord. 
Finally, the prodynorphin is found in the posterior pituitary and brain 
(Kh.achaturian et al., 1982; watson, 1982, 1983). It has been found in 
several hypothalamic cell groups and brai.n stem, as well.. SOme pathways 
are known (supraoptic nucleus to posterior pitu:itary) ( Akil. et al., 1984) 
whereas others are still to be studi.ed. 
These three opioid neural pathways, will. now be described i.n more detail. 
Since the majority of studies have deal.t with the regional distribution of 
enkephalins, they will be considered first. 
3.1. EnkephaLtn-tmmunore~tve neurons. 
Most observations have been made in the CNS of experimental. anima.ls. 
However, a very simiLar distribution of enkephalin-immunoreactive 
neurons has been demonstrated by CUell.o (1978) in human CNS. A 
notable observation is that enkephal.in-immunoreactive neurons are 
l.ocated in high concentrations in areas related to pain and anal.gesia 
in the mammalian nervous system (HOk£el.t et al.., 1977; Simantov et 
al., 1977). Although minor discrepancies are found between the 
results of several authors the fol.lowing pattern of enkephalinergic 
distr~ution emerges (Fig. 2): 
Telencephalon. Numerous cell bodies occur in the n.caudate putamen, 
n.accunibens and n.l.nterstitialis of the stria terminal:is. occasional 
cell bodies can also be found in the olfactory- and frontal cortex. 
Furthermore,. enkephalin-i.mmunoreacti.vity was found in the limbic 
system, with significant amounts of the enkephal:ins in the 
hippocampus, more specifically i.n the pyramidal neurons (Gall et 
a.J.., l98l) and fibers in the CA
2 
(Finl.ey et al.., 1981). Both groups 
found enkephalin-immunoreacti.vity in the granul.e cells of the dentate 
gyrus. The most important enkephali.nergic fiber system. of the entire 
brain is found in the globus pal.l.idus, which seems to receive an 
enormously heavy input of enkephal.inergic 
erikep~in-immunoreactive cell bodi.es are 
fibers, 
restricted 
while 
to the 
neighbouring caudate putamen (CUello, 1983). cell bodi.es and fibers 
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can al.so be detected in the n. amygdale ides medialis and centralis. 
These neurons appear to :be the site of origin of some of the 
etikephalinergic fibers te~nating in the n.interstit1alis of the 
stria terminalis ( Ohl et a1., 1978). 
Diencephalon. The hypothalamus seems to di.sp1ay a large n\llllber of 
enkephalinergi.c cell bodies. Intens enkephalin-immunoreactivity was 
found in the perifornical region. cell bodies directly associated 
endocrine functions (n.arcuatus, supraopticus 
paraventricularis) 
al., 1978). 
display enkephalin-immunoreactivity (sar 
and 
et 
Brain stem. and cerebell.um. Rel.ativel.y few enkephalin-i..n:Dnunoreactive 
cell bodies and enkephalinergic fibers are found 1n the substantia 
grisea, while high concentrations are found in the parabrachial nuclei 
and dorsal. tegmental nucleus. Very low concentration of enkephalin 
can be detected in the cerebellwn. 
Spinal cord. 
fibers is 
An intense 
funiculus. 
and are 
The highest concentration of enkephalin-immunoreactive 
present in the most superficial layers of the dorsal horn. 
f~r network is also observed in the dorsolateral 
scattered fibers are seen all over the substantia grisea 
particularly distinctive around the motorneurons 
(CUel.lo, 1983}. 
3.2. ~-endorphtn ~mmunore~ive neurons. 
The first clear evidence for distinctive and separate populations of 
~ndorphin- and enkephalin-containing neurons comes from the work of 
Bloom et al.. (1978). .e-endorphin-contal.ning elements (Pig.2) a:r:e 
highly concentrated in the bypothal.amus. According to Bl.oom et 
al. ( 1978) the cel.l bodi.es of these neurons are clustered in the 
arcuate nucleus and tuberal region. The fi..her system originating from 
these neurons is distributed rostrall.y in the region of the anterior 
comm:isure extending into the lateral septum and n. accunibens. The 
loose fiber system of the periventri.cul.ar regions of the hypotha.l.a:mus 
appears to continue dorsally and terminate in a number of brain stem 
structures prom.i.nently in the periaqueductal grey matter and the l.ocus 
coerul.eus. Bl.oom et al. ( 1978) also found immunoreactive fibers in 
the ol.factory cortex and hippocampus. 
OB c 
POA I 
I I 
I I 
I I 
G~nST 
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HP 
I 
nPV 
nSO H A 
LC sgc 
~g.2. Saggt~a~ vteu Of ~he rat bratn representing the dtstrt.button of the 
ma.J'or neurona~ systems contat.nt.ng enk:ephaZ.t.n (e-) and eru:to:rpht.n (a ---) 
t.mJmmoreac-ttve neurones. OB: OLfac-tory buLb; CP: cauaatus putamen; BP: 
hippocampus; POA: preoptic area; GP: GLobus paLLtaus; nST: nucLeus 
tnterstt.ttaLts of the strta te~naLts; nso: nucLeus supraopttcus; nPV: 
nucLeus paraventrtcuLarts; B: hypothaLamus; A: amygaaZ.a; sgc: 
substantia grtsea centraLts of the mtd-bratn; LC: Locus coeruLeus; nT.S: 
nucLeus tr~us soLttartus; sgSC: substantta geLattnosa of the sptnaz. 
co:rd;(modified after CUello, ~983). 
3.3. Dynorplrf..n-t.Jl'Ul'W.noreact"tve neurons. 
It bas been pointed out that dynorphin-~noreactive neurons belong 
to a subset of opioid-containi.ng neurons (Watson et al., 1981.). In 
£act some of the immunoreactivity attributed to the enkepbalins could 
be due to the presence of dynorphin, as many antibodies against the 
enkepbalins can potentially cross-react with dynorphin-immunoreactive 
material, mainly at the high concentrations used in 
- 22 -
immunohistochemistry. This seems to be true for the 
enkepbal~n-immunoreactivity present in some neurosecretory neurons o£ 
the hypothalamus (watson et aJ.., J.982). A clear distinction between 
these opi.oid immunoreactive neurons has still to be made. 
4. OPIOID PEPTIOES AND TBE BLOOD BRAIN BARRIER. 
An insignificant permeability through the blood-brain barrier a£ter 
systemic administration of opioids would appear consistent with the view 
that the blood-brain barrier, which is composed of cerebrovascular 
endothe1iaJ. ceJ.ls that are connected by tight junctions, is essentially 
i.mpermeable to water-soluble non-electrolytes, electrolytes, peptides and 
proteins ( Rapoport, 1976). 
Because of their limited cerebrovascular permeability, it has been 
suggested that circulating peptides enter the brain via the chorioid plexus 
and cerebrospinal fluid (Cornford et al., 1978), or, if produced in the 
pituitary~ through routes such as the pituitary portal system (Klee, 1977). 
In contrast, some investigators have reported that peptides are 
significantly permeable at the blood-brain barrier (Kastin et aL, 1976; 
Voightlander and Lewi.s, 1978)~ and that lipid solubility may play a role in 
the peptide transfer through the blood-brai.n barrier (Rapoport et 
al., 1980). 
These investigators a1so demonstrated that some synthetic analogues of 
natural opioid peptides have a moderate cerebrovascular permeability, at 
least sufficient to produce significant brain uptake. There may be little 
uptake after a bolus injection if the peptide disappears rapidly from 
pLasma~ or if binding to plasma protein is marked. However~ the fact that 
opiates, administered systemi.cal.ly~ exert central effects (Yamashiro and 
Tseng, 1977) suggests a significant cerebrovascular permeabil.ity (Rapoport 
et aL ~ 1980). This permeability indicates, furthermore, that feedback may 
operate between circulating peptides that have potential central effects, 
and brain sites that regulate their release into circulation (DeWied~ 1977; 
Klee, 1977). 
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Cll1\PTER II. 
OP lATE RECEPTORS 
1.. DEK>NSTRATION AND PROPERriES OF THE OPIATE RECEPTORS. 
The d1rect demonstration of specific saturable binding of opiates to 
nervous ti.Ssue was reported simultaneously by Pert and Snyder ( 1.973), Simon 
et al.. ( 1.973) and Terenius ( 1973). The abi1i.ty to assay spec:ific opiate 
binding sites directly wl.th l.abel.J.ed opiates and opiate antagonists of high 
specific activity has permitted us to learn a great deal about these sites 
and to provide evidence that they are the pharmacologically relevant opiate 
receptors. 
Receptors are defined as specific sites to which a drug must bind in order 
to trigger biochemical or biophysical steps that result in the observed 
pharmacological response (Simon, 1982). 
Opiate bindi.ng sites, present in the CNS and in some innervations of 
peripheral. organs, are tightly bound to cell membranes in the vicinity of 
synapses. They have been found in all vertebrates so far examined and in 
some :invertebrates as well (Stefano et aL, 1.980). 
The opiate binding is saturable, reversible and stereospecific. Only the 
active enantiomer of an opiate binds with high affinity (Simon, 1982). The 
most convincing evidence for pharmacologically relevant opiate receptors, 
comes from the excellent correlation between binding affinities and 
pharmacological activity of opiates that vary in potency (Stahl et 
al., 1977; Creese and Snyder, 1975). opiate binding is very sensitive to 
a variety of proteolytic enzymes and reagents that react with functional 
groups and amino acids of the protein. In particuJ.ar, sulfhydryl reagents 
have been studied in detai.l and all such reagents have been found to 
inhibit specific opiate binding. Evidently, one 
containing a sa group participate in the binding process. 
or more proteins 
The fact that 
opiate rece~ors are highly sensitive to some phospholipases, as well as to 
low concentrations of detergents suggest that phospholipids also play a 
role, possibly holding the receptor site in the active conformation 
(Pasternak and Snyder, 1973). 
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A very specific effect on opiate binding is exerted by sodium ions and, to 
a l.esser extent, by lithium. ions. All other cations, including the closely 
related a.l.kal.i metals, tend to inhibit the binding of all ligands to the 
opi.ate receptor in a dose-related manner (Pert et al., 1973; Simon et 
al., 1975). Accumulating evidence suggests that Na+ acts as an allosteric 
effector, shifting the equilibrium towards a conformer of the receptor that 
binds antagonists with greater affinity than agonists (Simon et al., 1975; 
Simon and Groth, 1975 ). 
2. MULTIPLE OPIATE REc::E:P'l'ORS. 
on present evidence it appears that there are in the central nervous system 
three independent peptidergic systems (Chapter I ) . 
The question arises whether or not these different opioid peptides interact 
with one and the same receptor or whether there are several receptors 
subserving different physiolog~cal functions. The latter is specia1ly 
important s~nce the synthesis of highly specif~c ligands for one receptor 
class would then become possible and could prov~de drugs of cl~n~cal. 
importance, such as analgesics with low add~ct~on potentiaL The existence 
of several endogenous opiate receptor ligands and the finding that multiple 
receptors exist for classical neurotransmitters such as acetylcholine and 
catecholamines stimulated the exam~nation of the possible ~tence of two 
or more op:iate receptors. 
Pharmacolog~cal differences between morph~ne and some synthetic analogues 
observed by Martin et aL ( 1976) in chronic spinal dog preparations 
suggested the existence of three types of receptors, which they named ~ for 
morphine, K for ketocycl.azocine and for SI<F 1.0047 (N-allyl 
norcyclazocine). After the discovery of the enk.ephalins Kosterlitz • s group 
found a paradox in the potency of opiates and enk.ephali.ns in two b~oassay 
systems. 'rhey concluded that two different receptor types predominate in 
the two tissues: A receptor in the guinea pig ileum that prefers morphine 
and its congeners, which they called the ~ receptor, according to Martin 
and coworkers, and one that prefers enkephalins :in the mouse vas deferens, 
which they called the s opiate receptor (Lord et al., 1977). Similar or 
:identical receptor heterogenity has been found in rodent and human brain 
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(Chang and cuatrecasas, 1979; Bonnet et al., 1981). 
The exact physiological significance of these multiple receptors is not yet 
fully understood but Wolozin and Pasternak ( 1981) suggest that the JL- and 
6-receptors may correspond to 
respectively, as determi.ned 
high- and low-affinity 
by ( 3s:)naJ.oxone binding. 
receptors, 
Even more, 
differential tolerance of the mouse vas deferens to J.L- and 5-s:pe:cifi.c drugs 
strongly supports the pharmacological relevance of the two receptors 
(Schu~ et al., 1960}. 
However, it is still not clear if we are deal.Ulg Wi.th two d'istinct 
receptors or with an opioid receptor complex, in which the erikephalin and 
morphine receptor are allosterically coupled (Rothman and Westfall, 1982). 
Many opiate drugs interact at multiple receptor sites. Thus the 
constellation of neuropharmacological actions of a particular opioid ligand 
may reflect its various potencies at a combi.nation of JJ., 5, K and <T 
receptors. However, some peri.pheral and pharmacologi.cal effects have been 
ascr~ to the different opiate receptor sUbtypes. For example, 
interactions with the JJ. receptor produce analgesi.a (Urea et al., 1977) 
mi.osi.s, bradycardia and hypothermia (Marti.n et al., 1976 ), whereas the 5 
opiate receptor can be held responsil:lle for epileptic (Urea et al., 1977), 
sedative (Harti.n et al., 1976) and behavioural (Urea et al., 1.977; Stein 
and Belluzzi, 1979) effects. Ketocyclazocine-like opi.ates produce ataxic 
and sedative effects and pupillary constriction via interaction with 
K-receptors ( Marti.n et al. , 1.976 ) , whi.le SKP 1004 7 and related opi.ates 
produce st~lant and psychomimetic effects after activation of <T-receptors 
(Holltzman, l979). 
3 • INTERAcriON WITH ENDOGENOUS LIGANDS. 
In Chapter I we described three different opioid systems. It i.s important 
to consider the activity at the different binding sites of the possible 
fragments of these precorsors. 
3.1. POMC-aer~ved. 
,13-endorphin is equipotent in displacing the binding of tritiated JJ..- or 
o-ligands (Kosterlitz et al., 1982). Furthermore, it does not 
interact with the K-receptor, the only opiate receptors present in the 
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rabbit vas deferens (Oka et al., 1.981.), even after the inhibi.tion of 
peptidase activity (McKnight et al., 1.982). 
3.2. Pro-enkephaL~n-dertved 
As already menti.oned (Met 5 )enkephal.in and (Leu 5 )enkepha.lin are present 
in this precursor. Both, and particularly (Leu5 )enkephalin, have a 
higher affinity for the s- than for the ~-binding site and are almost 
inactive at the K-binding site. 
In b:inding assays, (Met5 )enkephal.yl.-Arg6-Phe7 (Stern et aL, 1979) and 
5 6 7 8 (Met )enkephalyl.-Arg -Phe -Leu (Kil.pa.trick et aL, 1.981.) do not 
distinguish between §.1.- and S-binding sites, however, the J.atter one is 
five times more potent. Both pepti.des have l.ow potencies at the 
K-binding site (Magnan et al., 1982). 
3.3. Prodynorphtn-dertved. 
The heptadecapepti.de dynorphin, dynorph:in1_ 13 
and dynorphin
1
_
13 
-amide 
interact preferentia.J.l.y with the K-bindi.ng site ( Chavkin et al., 
1982; Corbett et al.., 1.982). 
Anal.ysis of the binding and phazmacological profiles of the c-terminus 
extensions of (Leu5 )enkephalin, derived from prodynorphin, has shown 
that the shorter peptides exhibit different patterns of selectivity 
(Corbett et al., 1982). In binding assays, any extension of 
5 - 1 (Leu )enkephal~n resu ts in a loss of a-selectivity, which is 
characteristic for the pentapeptide (Paterson et al., 1983) and a 
progressive increase in agonist potency at the ~-binding site (Corbett 
et aL, 1982). 
The fact that the antagonist Mr 2266, which interacts ~th M- and 
~-opiate receptors, is more potent than the ~ antagonist, naloxone, 
against a- and J3-neoendorphin, supports the view that these peptides 
interact with the K-receptor as well ( Oka et al., 1982). 
4. DISTRIBOTION OP OPIOID RECEPTORS IN THE BRAIN. 
4.1. Reg~onaL a~s~r~bu~~on Of opto~a rece~or b~na~ng. 
Advances in technology of receptor autoradl.ography allowed detailed 
histochemical mapping of opioid receptors l.n rodent and primate brain 
{Atweh and Kuhar, 1977 a,b,c; Pearson et al., 1980; Wamsley et al., 
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1982). Except for minor differences~ the distribution of receptors is 
very similar in the different species, studied. 
AJ.though opiate receptors are wide~y distributed in the brai.n, they 
can be observed most often in association with three major systems: 
L sensory system; 2. Limbic system; 3. Neuroendocrine system. 
4.1.1. opiate receptors associated with sensory systems. 
A high density of opioid receptors is found in the spinal cord and 
the brai.n-stem in associ.ation wi.th afferent systems. In the spinal 
cord, genera11y higher receptor densities are found in the grey 
matter compared to the white matter. High receptor density can be 
observed in the dorsal horn and specifically in the marginal cell 
zone and in the dorsal J.ayer of the substantia gel.atinosa (s.g. ). 
In the upper cervical cord and in the lower medulLa, these receptors 
seem to be continuous w:ith:i.n the s. g. of the descending spinal 
nucleus of the tr'i.geminal. nerve (Atweh and Kuhar, 1977a). 
The s. g. of the sp'inal. cord and the trigeminal system is an 
important structure for the transmission of sensory informa.t'ion, 
such as temperature and pain, to the CNS. Opiate receptors in the 
s. g. are strategically located to modulate this transmission of 
nociceptive sensory information. The ilnportance of those receptors 
i.n expl.a'ining the ana.J.gesic properties of opiates, is supported by 
many phys'iol.ogical. and clinical experiments (McClane and Martin, 
1971; Krivoy et al.., 1973; cal.v'ill.o et al., 1974; Yaksh and Rudy, 
1976). 
The other mechan'ism by which opiates exert their analges'ic 
properties involves the higher centres in the mid-brain and 
thalamus. The per'iaqueductal. grey matter in the mid-brain is 
probably an important area for the control of pain (Mayer and 
Liebesk:i.nd, 1.974; Richardson and Akil, 1.977) and is found to be 
hi.ghl.y enriched wi.th opiate receptors (Kuhar et al., 1973; Atweh 
and Kuhar l.977a). 
Certain sensory nuclei of the thalamus are al.so found to be enriched 
with opioid receptors (Atweh and Kuhar, l977b), specifi.call.y the 
periventricular nuclei., that are known to be important in the 
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processing of nociceptive si.gnals (Pert and Yaksh, 1.974). Opioid 
receptors are found as we11 in the afferent fibers 
nerve and their terminals with:ln the n. tractus 
n.comml.ssuralis (Atweh and Kuhar, l.977ai Wamsley 
of the vagus 
solitarius and 
et al.., 1.982). 
Those receptors may underlie the mechanisms by which opiates affect 
certain autonomic functions such as blood pressure control (Fennessy 
and RattJ::ay, 1974), respiration (Morin-surun et al., l.984a,b) and 
gastric motility (Yamaguchi, 1.974). 
4 .1.. 2. Opioid receptors associated with the limbic system . 
In the forebrain the highest concentration of opiate receptors is 
associated with the amygdala and basal ganglia. The n.amygdaloides 
corticalis, medialis and basalis, show the highest receptor 
concentration. This is most pronounced in the cortical layer (Atweh 
and KUhar, l977c). The basal ganglia also show a widespread 
distribution of opioid receptors, specially in the striatum, where 
they are located i.n clusters of high densi:ty and in a streak 
locali.zed to the superior 
below the corpus callosum 
and lateral boundaries of the striatum 
(subcollosal streak). There is only 
moderate and diffuse enrichment of opiate receptors in the globus 
pallid us. Patches of receptors are also seen i.n the n. accumbens, 
but their density is not as high as those seen in the caudate (Atweh 
and Kuhar, l977c; Wamsley et al., 1982). Since these structures 
play an important role in behaviour and mood control, the 
interconnections, specia1ly in the striatum, between the 
erikepalinergic system and the dopaminergic system, has received a 
lot of attention It is suggested that some of the opioid 
receptors are located on the dopaminergic termi~s. 
presynaptically, within the striatum (Pollard et al., 1978; Murrin 
et al., 1980). Indeed, pharmacological studies demonstrate that 
opiates do irihibit dopamine release in the striatum (Loh et 
al., 1976). 
Electrical stimulation of the caudate (Lineberry and Vierck, 1975) 
and direct injection of morphine in the rat striatum ( Jurna and 
Heinz, 1979) have been shown to have anti.nociceptive effects. The 
striatal opiate receptors may contr~ute to these analgesic effects. 
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other areas in the forebrain that possess op~ate receptors are the 
cortex and the hippocampus, specially the pre subicular area ( Atweh 
and KUhar, 1977c). In vitro labelling of opioid receptors Ln tissue 
sections of rat and monkey brain, fol.lowed by autoradiography, 
however, revealed variable receptor densities in the hippocampus and 
cortex (Goodman et aJ.., 1.980; Duka et al.., 1981). 
It is generall.y assumed that the pbyl.ogenetical.l.y ol.der parts of the 
cortex, such as the hippocampus and the cingulate gyrus, show higher 
densities of opiate receptors ( Meibach and Maayani, 1980; 
et al.., 1992). 
4.1.3. Opioid receptors associated with neuroendocrine systems. 
Wamsley 
It is well known that opiates exert some effect on both posterior 
and anterior pituitary function (Chapter I). Their effect on the 
posterior pituitary is probably roediated by those receptors present 
in the posterior lobe (W'alllsley et al., 1982). Very high receptor 
density is seen in the infundibuJ.um of the hypothalamus. These 
receptors seem to be particularJ.y interesting, since many of the 
hypothal.amic reJ.easing factors that control. the secretory functions 
of the anterior pituitary are reJ.eased from neurosecretory nerve 
endings i.nto the capiJ.J.ary bed of the infundibuJ.um. There is some 
evidence that opi.ates do irihibit the release of hypothalamic 
releasing or inhibitory factors, such as thyrotropin-releasing 
hormone, somatostatin (which regulates the release of growth 
hormone) and dopamine (which inhibits the release of prolactin) 
(Meites, 1980). Hypothalamic nuclei are aLso enriched ~th opiate 
receptors (Kuhar et al.., 197.3; Atweh and Kuhar, J.977b). In 
addition to the neuroendocrine systems, other vegetative functions 
of the hypothalamus, such as temperature reguLation and feeding 
behaviour, may also be affected by opiates (Chapter III). 
High density of opiate receptors is found in the rat mid-brain in 
association with the visual. system ( Atweh and Kuhar, 1977b). 
4.2. ~fferent~atton of ~ ana S optate receptor dtstrtbutton. 
The localization of J.L and S opiate receptors in the cerebral cortex is 
strikingly different. J.L receptors are localized to discrete clusters 
and a subcol.J.osal. streak (Young and Kuhar, ~979; Goodman et al., 
1980) in the caudate putamen~ whereas 8 receptors are more diffusel.y 
distributed. 
The most str1king difference in l.ocali.zation between the two receptor 
types occurs in the thalamus and hypothal.amus. The dorsomedial and 
ventral. thalamus, as wel.l as the hypothal.amuS~ contain a very high 
concentration of p.. receptors and extremely few s receptors (Goodman et 
al..~ 1.980). The paraventricular nuclei of the hypotha.l.am.us are 
enriched with 8 receptors (Duka et aL, 1981.). 
8 receptors are d:istributed diffusely in the hippocampus, while p. 
receptors are highJ.y locaJ.ized in the pyramidal. eel.~ layer. 
The olfactory tUbercle, n.accumbens and amygdaLa have high densities 
of 8 opiate receptors and relati.veJ.y few p. sites. The septwn contains 
8 opiate receptors as well ( Duka et aL, 1981). Areas with the 
highest concentration of p. receptors incJ.ude the brain stem, 
periaqueductal grey and n.interpeduncul.ar (Goodman et aJ..~ 1.980; Duka 
et al., 1981). 8 opiate receptors are only found in the pontine 
nuclei. Similar high densities of the two receptor types occur in the 
medulla obJ.ongata, spinal cord, n. tractus sol.itarius, grey matter 
areas and the substantia gelatinosa. 
A variety of opiates show different rank order of potency 
and 8 opiate receptors (Chang and cuatrecasas, 1979; 
al. ~ 1979). Larsson and his coworkers ( 1979) showed that 
for the p. 
Chang et 
(Met)- and 
(Leu)-enkepha.lin are contained, at least in part, in separate neuronal 
populati.ons. Snyder and Goodman ( 1980) suggested that the JJ. and 5 
opiate receptors are the physiol.ogi.cal receptors for (Met)- and 
(Leu)-enkephali.n neurons, respecti.ve1y, since for exampJ.e the 
amygdala, which possesses more 8 than p.. receptors, contains more 
(Leu)- than (Het)-enkepba.lin neurons, as well. 
p.-selective erikephalin analogues are more potent analgesics than 
8-selective peptides, which agrees with the p. receptor localization in 
brain regions subservi.ng pain perception (thalamus, spinal cord, 
periaqueductal grey). 8-specific enkephali.ns are more effective in 
eliciting limbic seizures (Urea et al ... 1977; Dzoljic, 1980) and in 
facilitating reward behavi.or (orca et al., 1977; stein and 
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Be1luzzi, 1979). Indeed, some limb:ic structures, such as the 
amygdala, n.acc:u.u:ibens and some hippocampal areas are enriched wi.th s 
opiate receptors (Meibach and Maayani, 1960). 
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cm>.PTER III. 
NEUROBIOLOGICAL PROPERTIES OF TBE OPIOID PEPT!DES 
L PRO- AND ANTI-coNVULSIVE ACTION OF THE OPIOID PEPTIDE$. 
To get a better understanding of these properties, most experiments are 
performed usi.ng mot:phine, since this opi.ate-~ike substance i.s well. 
known for its analgesic action and presumed to be a ~-opiate agoniSt. 
Relatively high doses of morphine or related alkaloids, administered 
systemi.caJ.ly or :intracerebroventricularly ( icv), induced electrographic 
epileptiform activity and behavioral convulsions in various species 
(Gilbert and Martin, 1975; Urea et a.J.., 1977; Aloisi et al., 1.980). 
However, electrographic epileptiform phenomena, observed after icv 
administration of etikephalins or P-endorphin are never associated ~th 
behavioral convulsi.ons (Orca et al., 1977; Frenk et al., 197Sb; 
Henriksen et al.., 1978; AJ.oisi et al., 1980) with exception of wet dog 
shakes (Prenk et al., 1978b; Chapter VII) and myocloni.c contracti.ons 
of the submandibular muscles (Dzoljic and vd Poel-Heisterkamp, 1982). 
Stibconvulsive doses of morphine may enhance the action of different 
convulsant manipulations ( Le Gal la Salle et al., 1977; Full.er and 
Ol.ney, 1979; orca and Frenk, 1980). However, anticonvuJ.sive 
potentials of morphine (Ad.l.er et aL, 1976 ), enkephalin analogues and 
,6--endorphin (Tortella et aL, 1981; Berman and Adler, 1984) have been 
detnOnstrated as well. Cowan et al..(l979) reported that opiates could 
be cLassified on the baSis of the change these compounds produce in the 
seizure threshold, and most of the opioids do increase this threshold 
(anticonvulsive). 
FUrthermore, it has been shown that opiates possess both pro- and 
ant:i.-convulsant properties, depending on the experimental conditions 
(Orca and Prenk, 1980). Similarly, pro- and anti-convulsive effects of 
naloxone, the opiate antagon:ist, have been observed (Snyder et 
al., 1981). 
Por an explanation, we must first examine the mechanisms, site(s) and 
receptor( s), mediating this dual effect. 
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1.1. The convu~san~ sys~em 
The doses of systemic or i.cv administered morphine, needed to produce 
electrographic and/or behavioral seizures are very high compared to 
the doses which produce analgesia ( Prenk et al., 197Sb) This precludes 
activation of specific opiate receptors. 
On the contrary, ,t3-endorphin and Leu- and Met-enkephalin produce EEG 
epileptic spikes at very low doses, whi.l.e high doses are needed to 
produce analgesia (Frenk et al., 1.97Sb; Henriksen et al., 1978). 
These epileptic phenomena are probably mediated by specific opiate 
receptors, which are different from the ~-receptors, presumed to 
mediate analgesia (urea et al., 1977). The high doses of naloxone, a 
preferential p. antagonist, needed to reverse enkephalin-induced 
seizures suggests that the 8 opiate receptors are involved ~ the 
opioid-induced epileptic phenomena (Prenk et al., 1.978a; Dzolji.c and 
vd Poel-Heisterkamp, 1.982). 
SUmmarizing, it appears that morphine and the opi.oid peptides, 
depending on the conditions of adm:inistration, activate two convulsant 
systems: 1. A non-specific system and 2. 
system. 
1.1.1. Non-specific convulsant system. 
A s receptor-mediated 
In literature, a role for the GABA-ergic system in the non-specific 
proconvulsant system is suggested (Dingledine et aL, J.97B; Dzoljic 
and vd Poel-Heisterkamp, 1981; Werz and McDonald, 1.982), although 
evidence for. glycine involvement also exists (Werz and 
McDonald, 1.982). 
Erikephalin markedly attenuates a variety of GABAergic inhibitory 
pathways in the CNS, but does not affect the action of GABA. (Nicoll 
et al., 1980). Since morphine, but not (D--ala2 ,D-met5 )enkephal.in, 
has an antagonistic effect on GABA (Nicoll et al., 1980; Werz and 
McDonald, 1982), the convulsant action is apparently not a factor of 
the putative S system. It is suggested that the site of action of 
this non-specific convulsant system may be located on those sites, 
where mo~hine causes epileptiform activity and the enkephalins do 
not (Frenk, 1983). Such sites exist in the cerebral cortex (Sprick 
et al., 1981) and spinal cord (Frenk, 1983). 
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L 1. 2. The 5-opi.ate receptor mediated proconvulsant system. 
Since iontophoretic application of opioid peptides typically 
inhibits neuronal firing in most bra:in areas, but excites the 
hippocampal pyramidal cells (Nicoll et al., 1977; French and 
Siggi.ns, 1980; Chapter IV), the hippocampus is proposed as the 
origin of the opioid-l.nduced seizures (Henriksen et al.., 1978). 
'rh.is hippocampal neuronal excitation is reversible by naloxone in 
most studies (Nicollet al., 1977; Zieglgansberger et al., 1979; 
Chapter IV). However, trd.croinjections of opi.oid peptides produce 
activatory and epileptiform effects on the local electrical activity 
not only in the hippocampus (French and S:igg:ins, 1980; Elazar et 
aL, 1982) but in other bra.J.n regions as well. such as the thalamus 
(Prenk et al.., 197Sa), n.accumbens, parietal cortex, amygdala 
(El.azar et a.J.., 1982) and caudate nucleus (Dzolji.c and vd Poel 
aeisterkamp, 1980). A non-susceptive area seems to be the 
per:iaqueductal grey (Yeung et al., 1978). 
In contrast to the suggestion that 5 opiate receptors mediate the 
excitatory phenomena (Frenk et al.., l97Sb; opioid-i.nduced 
ozoljic, 1982; Dzoljic and vd Poel-Heisterkamp, 1982), Gahwiler 
( 1981) demonstrated that receptors are involved in the 
opiate-induced hippocampal firing. However, this ~ght be a result 
of using (D-ala2 ,D-leu5 )enkephalin, which has a low discrimination 
rati.o between 5 and opiate receptors (Kosterlitz and 
Paterson, 1980), while the experiments were performed on cultured 
hippocampal cells and the results in vivo might be different by a 
recurrent i.nhi.bitory mechanism. 
1.2. The an~£convutsan~ sys~em. 
The anticonvulsive effects of morphine and the opioid peptides can be 
reversed by naloxone and only low doses of these subst~~ces are needed 
to produce the anticonvulsant action (Cowan et al., 1.979; Orca and 
Prenk, 1980; Tortella et al., 1981). Furthermore, since morphine 
decreases spontaneous and enkephalin-induced electrographic 
epileptiform spike activi:ty, it is suggested that activation of p.. 
opiate receptors result in an anticonvulsive effect 
(Dzoljic, 1982), which includes the existence of a tonically active 
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anticonvulsant system modulated by the endogenous opioi.d peptides. 
1.3. In~er~ton be~~een ~he pro- and an~tconvu~san~ sys~ems. 
The presence of a pro- and anti-convulsant system, both activated by 
the same substances and mediated by possibly pharmacologically 
different opiate receptors, raises the question whether it is possible 
to activate one, but not the other. 
Morphine derivates with diminished opiate receptor potency are 
demonstrated to possess an enhanced epileptogenic potency ( La.Bel.J.a et 
al., 1979). 
orca and Frenk ( l9S2i 1983) have shown that the pro- and 
anticonvulsant effects of morphine, {3-endorphin and Leu-enkephalin, 
may be elicited probably by employing different routes of 
administration and that the opiate anticonvulsant ~ system was able to 
inhibit the proconvul.sant 5 system (Chapter VI). 
The existence of the two systems might explain the dual effects of 
morphine, the opioid peptides and naloxone. Morphine as a Jl. agonist, 
in low doses, can be considered as an anticonvulsant agent (Adler et 
al., 1976; urea and Prenk, 1980). However, in high doses it might 
interact with s receptors as wel.l (WO.ster et al., 1980) and 
facilitate seizure phenomena induced by other convulsant agents 
(Puller et al.., 1979). This is partially in contrast to the 
hypothesis of Prenk (Prenk et al., 1982; Prenk, 1983), who proposed 
along with the non-specific and s-receptor mediated convulsant 
systems, a Jl. receptor mediated proconvulsant system. ru.s hypothesi.s 
is mainly based on the criterion of naloxone revers1bility. However, 
naloxone, which possesses a significantly higher blocking affinity for 
the p.. than for the s opiate receptors (Chang et al., 1980) can also 
antagonize the effects of Gl\.BA in high concentrations (Dingledine et 
al., 1978), leading to excitatory phenomena, independent of 
opioid-mediation. FUrthermore, pharmacologically, pro- and anti-
convulsive effects mediated by the same receptor subtype, is not 
comprehensible. 
Sim.il.arly, naloxone may faci.l.itate se:i.zure activity (Gilbert and 
Martin, 1975; 
high doses 
Schreiber, 1979; Snyder 
may block 8 receptors as 
et al., 1980, 1981), or in 
well., resul.ting in an 
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anticonvulsive effect (Dzoljic, 1.982). 
The recently described opioi.d antagonism of electroshock- and 
kindling-induced seizures (Berman and Adler, 1984; Pugl:isi-Allegra et 
al., 1984), might depend on the route of administration. The 
convulsions induced in these experiments are probably the result of 
the increased endogenous levels of endorphins and enkephalins (Hong et 
al., 1979; Vindrola et al., 1981). In th:is case, it should be 
interesting to examine the effects of enkephal.inase :i.nhibitors, like 
phospboramidon and thiorphan, which potentiate the endogenous 
enkephal.inergic system, on electroshock- andfor kindling-induced 
seizures, since it has been demonstrated that phosphoraJ:nl.don can 
induce epileptic phenomena, when a.dm.l.nistered alone ( Ukponmwan and 
Dzoljic, 1984). 
Thus, depending on the e~rimental conditions (pri:marly the dose of 
the opiates) and the functional activity of the endogenous 
en~orphinergic system, both pro- and anti- convulsant effects of 
morphine and the opioid peptides may be expected. 
2. OTHER NEUROBIOLOGICAL PROPERTIES OF THE OPIOID PEPTIDES. 
The most common pharmacological use of opiate substances is for the relief 
of pain. Indeed, ,e--endorphin and enkephalins, administered icv or 
systemically, induced analgesia (Wei et al., 1977; Poley et al., 1979; 
Kastin et al., 1979) while opioid antagonists enhanced nociceptive 
reactions (Jacob and Ramabadran, 1.978). Furthermore, several investigators 
reported that acupuncture involved an activation of endorphin-mediated 
analgesia (Pomeranz and Chiu, 1976; Mayer et al., 1.977). The results led 
to the conclusion that endogenous opioid peptides may be endogenous 
analgesics (Kosterlitz, 1.979; Terenius, 1982). 
Opiates are known to have mood-altering properties, such as dreamlike 
euphoria and reality escape, for which they presumably are 
self-administered in many forms and preparations. Many drugs that are 
abused by man, are self-administered by animals as well, and this includes 
the opiates like morphine and heroin (Werner et alq 1976) as well as 
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Leu-enkephalin (Belluzzi and stein, ~977), which 
endogenous euphorigen. Although many experiments have 
elucidate the underlying mechanisms of opiate 
tni.ght serve as an 
been performed to 
addiction;tolerance 
(Wei, 1981; Ztik~ and ZUkin, 1981; ZUkin et al., 1982), the diversity in 
natural opioid agonists and in antagonist ligand binding sites prevented 
the determination of involvement andjor mechanisms of the endogenous opioid 
system(s). 
Systemic injection of opioids results in locomotor activity, which is jerky 
and undirected, interrupted by grooming and staring (Koob and Bloom, 1.983) 
and wet-dog shakes (Chapter VI). In high doses, it might result in extreme 
generalized muscular rigidity (wand et al., 1973). An opio:i.d-dopamine (DA) 
interaction is proposed (St::i.nus et al., 1980), which might be of :importance 
for the putative ro1e of the mesolimbic DA system in the pathophysiology of 
schizophrenia (Bloom et aJ.., 1976; Jaquet and Marks, 1.976) and affective 
disorders (Judd et al., 1.981). 
Opioid peptides block the release of catecholami.nes ( Loh et al., 1.976; 
Taube et al., 1976) and some other neurotransmitters (Beaumont and 
Hughes, 1.979). This is attril:>uted to a presynaptic inhibitory action 
(Snyder and Childers, 1.979). In addition, they inhibit both spontaneous, 
and acetylcholine- or glutamate-induced f:iri.ng of most neurons, with the 
exception of hippocampal pyramidal cells and spinal cord Renshaw cells 
(Zieglgansberger and Bayerl, 1.976; Snyder and Childers, 1979). This 
inhibition of firing suggests an influence on post-synaptic receptors. 
Whether pre- or post-synaptic, the physiological significance may be in the 
fact that enkephalin- and endorphin-containing fibers usuaLly run in the 
vicinity of catecholaminergic fibers (Terenius, 1982). 
Intravenous or icv administration of opioid peptides stimulates pituitary 
release of prolactin and growth hormone (Grandison and Guidotti, 1977; 
Rivier et al., 1977). It is not known whether this effect is caused by a 
direct action upon the hypophysis, or by way of inhibition of the 
catecholami.nergic fibers, which normally control pituitary secretion. The 
latter explanation appears to be more likely (Beaumont and Hughes, 1979). 
Morphine, heroin and opioid peptides stimulate feeding and drinking (McKay 
et al., 1.981; MOrley et al., 1983), while opiate antagonists possess 
anorexic properties ( Bolltzman, 1979). stress-induced eating is shown to 
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be mediated by endogenous opiates, as well (Morley and Levine, l.9SO)a 
Although an overwhe~g body of evidence favors a role for the endogenous 
opioi.d peptides in the regulation of ingestive behavior, the exact 
mechani.sm. of action i.s not clear (Morley et aL, 1983). 
An involvement of the different opiate receptor subtypes, and as such of 
the different opiate agonists and antagon~s on respiration, is reported 
by several authors (Florez et al., 1980; Meldnon and Isom, 1981.; Hassen 
et al.., 1982). Where the ~ agonist does not change the respiratory 
frequency, the s opLate agonist results in a respiratory depression 
(Mor:i.n-Surun, 1984). 
Although the heart i.s devoid of opiate receptors (Si.mantov et al., 1.978 ), 
opioi.d pepti.des do alter cardiovascul.ar functions as well ( Bolme et 
aL, 1.978; Chapter VIII), generally resulting in hypotension and 
bradycardia. These effects are believed to be, in part, a consequence of 
opiate act1on upon the brain stem autonomic centers invo1ved in the 
regu1ation of cardiovascuLar homeostasis. Pituitary endorphins re1eased 
during stress or shoCk, probab1y act on opiate receptors in the brain to 
depress cardiovascular function ( ao1ad.ay and Lob, 1981). 
DeSpite the 1ong history of opiate thermoreguLatory investigations, the 
effects of opiates on body temperature are sti11 the sUbject of scientific 
controversy. In general, opiates may produce either hyperthermia (Martin 
and Morrison, 1978; French, 1979) or hypothermia (Lin and Su, 1979; Tseng 
et al., 1979), depending on species, doses, ambient temperature, route of 
:injection, degree of to1erance and endocrine status. General1y, it is 
conc1uded that endorphins may be activated by any extreme temperature 
(Thornhi11 et aL, 1980) and that the pituitary endorphins are more 
functionally invo1ved in heat adaptation in an associated hypothermic ro1e 
( Ho1aday and Lob, 1.981). 
Last, but not 1east, opioid peptides pLay a ro1e in memory and learning 
processes, where they are probably the mediators of an endogenous amnesic 
mechanism (Izquierdo et al., 1980). 
In general., it seems that the endorphinergic system does not play an 
expl.ici.te ro1e during homeostatic conditions within an organism. However, 
environmental or physio1ogical. al.terations, which may be considered as 
stressfu1, appear to activate this system. 
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CHAPTER IV. 
OPlATES AND HIPPOCAMPUS 
1. STRUCTURE AND NOMENCIATORE OF THE HIPPOCAMPUS 
The hippocampal region is the part of the cerebral cortex that forms a 
relatively long, horn-shaped body along the curvature of the 1ateral 
ventricles. This region can be sUbdivided in the hippocampus or 
Am:non • s horn; the fascia dentata (gyrus dentatus); and the subicul.ar 
region ( prosubicuJ.um, subiculum, presubiculum and parasubiculum), which 
:is contiguous to the entorhinal cortex (Fig .l.. ) . 
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Ng .1. Dtagram Of a hort.zonta~ sec"tt.on of the hippocampal, regt.on. The 
foLLout.ng ht.ppocampa'L Layers are shoun: aLveus; stratum ort.ens (s.o.); 
stratum pyramidaLe (pyramt.aaz, ce'Lt bodies, s.p.); stratum radt.atum (s.r.); 
In the dentate area: stratum granu'Losum (granu'Lar ce'L'L bodies, s.g.) ana 
the ht.Lus of the fascia dentata (ht.~.f.a.). The fo~~o~~ng re~a~ed 
s~ruc~ures are ~na~ca~ed: subt.cuMun; presubt.cu~um (pre-); parasubt.cu~um 
(para-); A: an~er~r; P: pos~er~or. 
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The Ammon•s horn (Comus Panmonis or CA) has been divided into 4 fields: 
CA1, CA2, CA3 and CA4 (Lorente de N6, 1934). '!'he CA2 and CA3 areas 
are the regions with giant pyramidal cel.l.s. The pyramidal. cell layer 
of the CA3 area enters the hilus of the fascia dentata ( CA4). 
According to Bl.ackstad ( 1956) these pyramidal cells fonn a deeper 
cortical layer which he called the .. dentate area". 
Since iontophoretically applied opiates and opioid peptides are known 
to excite hippocampaJ. pyramidal cells (Nicoll et al., 1977), a 
simplified diagram of the neuronal circuitry in the CAl region is given 
in Fig.2., illustrating excitatory and inhibitory synaptic connections. 
The pyramidal. cel.l. body l.ayer (stratum pyramidale) and the basal 
dendritic l.ayer also contain non-pyramidal cells, being used to 
descrihe basketcells and other inhibitory interneurons. Specific 
interneurons forming synapses excl.usively with the axon initial 
segments of pyramidal cells, have been identified by So~ et al. 
(1983). 
Schaffer 
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(nP). 
<+>y~ 
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pyramidal cell soma 
~g.2. Schema~~c represen~a~~n Of ~he neuronaL c~rcu~~ry in ~he CA1 
pyramidaL ceLL region of ~he h~ppocampus. P:pyramidaL 
NP:non-pyramidaL ceLLs; +:ezct~a~ory synapse; -:tnhtbi~ory 
!.:jeearo~ara tnhtbt~ton; 2.:feedback tnhtbt~ton. 
ceLL; 
synapse; 
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2. OPIOID MEDIATED HIPPOCAMPAL EXCITATIONS 
Cl1ni.cal and preclinical investigations of the endorphins have 
suggested a correlation between certain neuropsychiatric conditions, 
limbic system and the central function of these pepti.des (Bloom and 
McGi.nty, 1981; Vereby, 1982). Despite the uni.fo1:m naloxone-reversible 
depressant action of opiates and opioid peptides in most brain regions 
studied, iontophoretic 
hippocampa]. pyramidal 
applications of these substances excite most 
neurons (Nicoll et aL, 1977) while the 
neighbouring granul.e cells are depressed (Tielen et al., 1981.). The 
excitatocy cholinergic (ACh) septal hippocampal pathway, can not be 
involved in this excitation, since scopolamine and atropine, ACh 
bloCking agents, as well as lesions of the septal nuclei, do not reduce 
the opioid-induced excitations (French and Siggins, 1980). These 
findings point to an autonomous role for the hippocampus in the 
epileptiform response and may underlie epileptic episodes induced by 
enkephalins (French and Siggins, 1980; Henderson, 1983). 
Three major hypotheses have been proposed to explain these excitatory 
phenomena in the BPC: 
2.1. exc~~a~ton by atstnhtbt~ton. 
There are two, probably GABA-ergic pathways in the HPC, which both 
utilize non-pyramidal. interneurons, and illustrated in Fig.2. as the 
feedforward and feedbackward inhibitory pathways. Zieglgansberger 
and coworkers ( 1.979) postulated that excitation of pyramidal cel.l.s may 
activate inhibitory interneurons via recurrent collaterals of their 
axons. This inhibitory circuit may be interrupted by the application 
of opiates, which exert their effect at the level of the cell body of 
the inhibitory interneurone, suppressing cel.l discharge (Nicol.l et 
aL, 1980). The resulting d:isinhiDition of pyramidal cells becomes 
evident as a strong excitation. This hypothesis was supported by 
several other investigators (Dunwiddie et al., 1.980; 
1.980; Robinson and Deadwyler, 1.981). 
Lee et al., 
If disinhibition is the 
pyramidal cells, then 
~rtant mechaniSm in opioid action on 
intracellular records should show diminished 
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inhibitory postsynaptic potentials (i.p.s.p. ). However, opioids did 
not reduce the i.p.s.p. 
Dingledine, 1981). 
in pyramidal cells (Baas and Ryall, 1.980; 
2.2. Facttt~~~n 
Baas and Ryan ( 1980) proposed that opioid pepti.des enhance 
transm:itter release from excitatory nerve terminals. Indeed, several 
groups of investigators did find increased excitatocy postsynaptic 
potentials (e.p.s.p.) after opioid appl.ication (Baas and Ryall, 1.980; 
Nicol.l et al., 1980). However, others failed to observe this increase 
(Corrigal and Linseman, 1980; Ounwidd:ie et al., 1.980; Dingledine, 
1981; Lynch et al., 1981). 
2.3. Increased efftctency of coupttng 
Opioids might act by facilitating the passage of the e.p.s.p. from 
the dendrites to the cell soma and thus potentiate the soma population 
spike activity (Dingledine, 1.981.; Lynch et al., 1.981; Robinson and 
Deadwyler, 1981). aowever, the excitation evoked by application of 
excitatory amino acids is not potentiated by opioids, as would be 
expected (Baas and Ryall, 1980; Dingledine, 1981). 
Although no final conclusion can be drawn from these results, the bulk of 
evidence favours disinhibition as responsible for the excitation of 
hippocam.pa.J. pyramidaJ. cells by opioid peptides. The question of the 
functional meaning of the opiate-evoked excitations in the HPC remains to 
be resolved. 
3. OPIOID SYSTEMS IN THE HIPPOCAMPUS 
By evaluating immunohistochemical. studies ( HOkfelt et al.., 1977; 
Goldstein and Gha.zarossian, 1980; Wamsley et al., 1980; Gall et al.., 
1981; Hong and Schmid, 1981), at least two possible opioid systems, 
identified in the BPC have been suggested. Potentially, the most 
significant pathway is descr~ by the dentate-granule cells-mossy fLber 
system ( corrigal, 1983), where dynorphin has been identified (Henriksen et 
al., 1982:), while dynorphin-containing cells are also found scattered 
throughout ~ and CA3-4 cellular fields, possibly representing a sUbclass 
of interneurons (Henriksen et al., 1982:). The second peptide system 
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derives from the lateral entorhinal/perirhinal cortex and appears to 
synapse on dentate granule cel.ls. This latter pathway contains 
enkephalin-immunoreactivity, but is devoid of dynorphin (Henriksen et 
aL, 1.982). Enkephal.i.n-l.ike immunoreactivity was found within the somata 
of three types of hippocampal. neurons: L granule cells of the dentate 
gyrus, 2. occasional pyramidal shaped cel.lS of field stratum 
pyrami.dale, and 3. varied scattered i.nterneurons. Of thi.s last group, two 
types of i.nterneurons were consistently seen. The first occupy the border 
between stratum radiatum and stratum pyramidale, whereas the second lie 
within the stratum radiatum of field CAl. Cells containing enkephalin-like 
immunoreactivity were also observed in the subiculum (Gall et al.., 1981). 
Thus, opioid peptide immunoreactivity in two major opioid peptidergic 
pathwayS of the hippocampal formation may represent the presence of two 
entirely different prohormonal systems. Furthermore, dynorphin, in 
comparison to Leu5-erikephali.n, induced a longer lasting excitatory spike 
activity in the EEG (Henriksen et al., 1.982). Although questions of the 
pharmacological action of exogenousl.y applied dynorphi.n and its release by 
stimulation of the mossy fibers remain to be answered, i.t might be that the 
dynorphi.n family plays an ilDportant role i.n the opi.oi.d-i.nduced exci.tatory 
phenomena as well. 
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CHAPTER V. 
CORRELATION BE1.WEEN THE DISTR!BUTION OF 3 B-LABELLED ENI<EPBALCN IN RAT BRAIN 
AND THE ANATOMICAL REGIONS INVOLVED IN ENKEPBALIN-INDUCED SEIZURES 
SUMMARY 
~e corre~a~~n ge~~een ~he d~s~rt~u~ton-of tvt aamtntstered S agonist 
[ BJ(D-a~a 1D-~eu )-enkephattn ({ BJOADL) and the ana~mtcat regtons 
tnvotvea tn the enkephattn-tnaucea setzures has been studtea tn rat by 
ustng an autoraa~raphtc methoa ana recoratng Of the eLectromyogram (EMG) 
and the eLectroencephaLogram (BEG). 
The resuLts tndtcate that ~tthtn 10 mtn, the raatoacttvtty of the tvt 
admtntsterea drUg reached aLL parts of the ventrtcutar system, tnctuatng 
t~e centraL canaL of the sptnat cora. Ho~ever, ~tthtn 2.5 mtn after tvt 
{ B]DADL, ~htch correspondS ~ the onset Of DADL-tnaucea setzures, the 
substance appeared matnty tn the Left LateraL ventrtcte and occastonatty ~n 
~he ~h~rd ven~r~cte. Dur~ng ~he f~rs~ 2.5 m~n ~he subs~ance pene~ra~ed 
regutar~y ~n~o ~he surround~ng periven~r~cutar ~issue of ~he s~ria~um, 
septum ana ht.ppocampus t.o a depth Of abou~ 100 son. The mos~ ~ntenst.ve and 
~ng tasting ep~teptt.c discharges, ezceeding 30 min ~ere observed t.n the 
h"£.ppocampus, in con~rast t.o the miLa and shor~-Lasting eLectrophysioLog~caL 
responses Of the sep~um ana corpus str"£.a~um. The e:perimen~s suggest that 
the short onset of enkephaLin-tnauced ezct.tatory phenomena is aue t.o the 
rapid dt.stributt.on ana penetration of the substance in ~he surrounding 
pert.ventricuLar ~t.ssue. According to these data, it t.s proposed that 
activation of opia~e receptors LocaLized ~i~hin ~he first 100 ~ of ~he 
periventrtcuLar, tt.ssue, mainLy in ~he hippocampus, is essen~t.aL for the 
~riggering of endorphin-induced seizure a~t.vity. 
1. INTRODUCTION 
There are 1ndications that some synthetic analogues o£ natural opioids and 
~ndorphin have a moderate cerebrovascular permeability and can exert 
central effects in conscious an~ when administered systemically (Tseng 
et al., 1976; Rapoport et al., 1980). However, the variati.on in the 
amount o£ the opioid peptides penetrating the blood-brain barrier and the 
high costs of the compounds are the main reasons that most studies with 
endogenous opioid peptides have followed the intraventricular ( ivt) route 
of administration. 
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unfortunately, many aspects of the ivt adtoj_ni.stration which ll:d.ght be of 
relevance for the interpretation of the results with endorphins, such as 
diStribution of peptides in the ventricular system or the volume of 
injection in relation to its clearance from brain tissue, are not 
sufficiently well known. Although the distribution of morphine and 
morphine-like substances have been studied by Herz and Teschemacher (1971), 
no data are available about the spread of various endopioids (=endorphins; 
Adler 1.980 ) after i vt adm.in:i.stration. 
There is evi.dence from previous studies (orca et al., 1.977; Frenk et 
aJ.., 1978; Dzoljic et a.J.., 1979) that endorphins may play a rol.e in 
epi.l.eptogenesi.S. one of the most potent seizure-inducing opi.oid pepti.des 
is (D-ala2 ,D-leu5 )enkephalin ( DADL) ( ozolji.c and vd Poel-Hei.Sterkamp, 
1982) . This peptide, which is also one of the most potent agonists at 8 
Opiate receptors known at the time these experiments were performed (Chang 
et al., 1990 ), induced epil.eptic phenomena wi.thi.n a few minutes after ivt 
administration and the effect l.asted for 3o-GO min (Dzoljic and 
vd Poel-Heisterkamp, 1991). 
The short onset of excitability indicates an involvement of brain 
structures in the cl.ose vicinity of the Lateral ventricles. Lack of 
knowledge about the spread of the exogenously ( ivt) appl.ied opioid peptides 
has prevented the identification of those brain regions involved in the 
initiation of endorphin-induced seizure phenomena. 
The aim of this study is to identify the anatomical regions associated with 
the enkephalion-ind.uced excitatory phenomena and to correLate the extent of 
drug diffusion into these regions with the manifestation of pharmacological 
activity. An autoradiograpbic method and electrophysiol.ogical recording is 
used to detect the onset and characteristics of enkephal.i.n-induced seizure 
activity in the periventricular regions and cortex. The distribution of 
( 3H)DADL (ivt) within the liquor system and its speed of diffusion into the 
periventricular tissue, is compared. 
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2 • MATERIALS AND METHODS 
2.1. An~ma~ expertments 
2 .l. L AUto:racliogr.ophy. 
MaJ.e rats ( Wi.stax strain, 175-250 g) were anaesthetized wi.th 
urethane (L2 gjkg, i..p. ). A steel cannula for ivt injections was 
implanted by means of a stereotaxic instrument (coordinates: 
AP +6.1 mm, L -L3 mm., a -4.0 mm from dura with lambda O). 
J.2.5 ~-tCi/l~J.l ( 3a)OADL (29 Ci/mmol) was administered by use of a 5 .u.J. 
Hamilton syringe. In each period of 1, 2.5, 5, 10, 30 and 60 min 
after the injection, 4 rats (i..e. in total 24 animals) were killed 
0 
by immersion in a mixture of acetone and carbon dioxide ( -70/-80 C). 
After a minimum of 10 ml.n the coxpse was taken out and immediately 
0 
transferred to a cold room ( -20 c) . 
The method used was accordi.ng to Ullberg ( 1954) . Frontal brain 
secti.ons 30 J.L in thickness, were prepared in a ccyostat (-20°C) with 
a Jung model tetrander microtome using scotch tape (Minnesota Mining 
810 ) as a support. The sections were freeze-dried and then placed 
in contact w.ith LKB Ultrofi.lm 3H. For il.lustration purposes, prints 
were made of the autoradiograms (enlargement x 8. 3 ) showing light 
and dark areas Which are regions 
rad:ioact:i vi ty, respecti. vely. 
of maximum and minimum 
A hematoxyl.ine-eos:ine colouring method was used for st~ning the 
sect:ions to achieve a better contrast between the different areas. 
Anatomical interpretation of the distribut:ion of the radioactivity 
is based on the atlas of KOnig and Kl.ippel ( 1963). To determ:ine 
the extent of diffusion into the br~n tissue, the penetration 
distance was measured from the wall of the l.ateral ventricle into 
the hippocampal, striatal and septal areas. 
Statistical evaluat:ion of the data was performed by the Student's 
t-test. 
2. 1.. 2. Electrophysiologi.ca1 recording. 
Six male rats (Wistar strain, 1.75-200 g) were anaesthetized wi.th 
urethane (1..2 gjkg,i..p.). A tracheal cannula was inserted and 
electrodes were implanted in the sUbmandiblar muscles for the 
- 61 -
registration of the electromyogram (EMG) and myoclonic contractions 
(MC) (Dzoljic and vd Poel-aeisterkamp, ~982), Spontaneous and 
drug-induced myoclonic contractions of the submandWular muscles 
were recorded by the method of Bieger et al. ( 1972). A steel cannula 
for ivt injections ( l.eft side) and electrodes in the left side of 
the striatum (AP +1..9 mm, L +3.5 mm., a: -5.1. mm), hippocampus 
(AP +2.4 mm, (AP -4.9 mm, L +4.0 mm, .S: -3.0 mm) and septum 
L +0.5 mm, s: -4.3 mm, with a measured from dura and bregma O) (de 
Groot, 1.972) were implanted stereotaxically. In addition, the 
electrocorticogram (ECoG) between the frontal. and parietal 
electrodes was recorded by means of a polygraph Grass model 7. 
0 
Rectal temperature was maintained between 36. 5 and 37.5 C. 
2.2. Drugs 
D-ala2-(tyrosyl-1.-3,S-3H]enkepha1in (5-D-leucine) (New England 
NUclear), is supplied in o. 02M sodium dihyd.rogen phosphate buffer, pH 
2.1. Before use the labelled compound was dried under ni.trogen and 
diluted ~th an appropriate solution of artifical cerebrospinal fluid 
(CSP) (l. mCi/SO~l) and adjusted to ps: 7. Specific activity of 
[ 3H]Dl\OL was 29 C:i./mmol. 
(r>-ala2 ,D-leu5 )-enkephalin (OAOL) (Peninsula Lab.) was diluted in CSF 
( 5 p.g/2p..l) • 
3. RESULTS 
The conclusions are based on a large number of autoradiograms of which, 
only a small selection is shown here. 
3.1. ~strtbutton of £3HJDADL tn t~e ventrtcu~ar system 
At 1 min after administration of labelled DADL (12.5 ~Ci/1~1), 
radioactivity was observed in all 4 rats only in the left lateral 
ventricle, where it was injected (Fig.l). After 2.5 mi.n, the 
radioactivity penetrated to the frontal parts of the third ventricle, 
the recessus ptnea~ts (in 3 of 4 animals) (Pig.2). However, within 5 
min the labelled substance reached both lateral ventricles and all 
parts of the third ventricle in all experimental animals (Pig. 3). 
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E'1,g .1. Brai-n secti.on (A 5780 J.l) ana correspondtng au~radtog:ram, 1 min 
af~er t.ntraventr~~arLy admtntstered Labettea (D·a~ ,g-teu )-enkephattn 
([ BJDADL, !2.5 ~/J.lL) tn t~e rat bratn. Note that [ HlDADL ~as onLy 
detected t.n tne ventrtc~e uhere tt uas i-njected. 
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Ftg.Z. Bratn sectt.on (A 3750 J.L) and correspond:i,ng au'tO:radt.ogram, 
af~er 2 sntraventrtcu~ ~ntstratt.on of 
(D·a~a ,D-~eu )-enkepha~tn (12.5 ~/J.LL) tn the rat bratn. Note 
raa~ttve sUbs~e penetrated tnw the thtrd ventr~Le. 
2.5 mt.n 
LabeLLed 
that the 
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Ftg .3. Bra-Ln sect ton ana correspond-Lng au-toradtog~am, s 5 mtn af-ter tn-traventr~~ar ~ntstratton of ~abe~~ed (D-ata ,D-teu )-enkepha~tn 
(12 .5 p.C"L/JLL) tn t'he rat brai:n. Note t1'le penetrati-on Of the raaioactt.ve 
substance tnto the corresponding LateraL ventrtcLe ana tht.ra ventrtc1e. 
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Ng.S. Brain sect.'ton (A 160 JJ.) and co:rTesponatng au~raa.t.ogsam, 10 mtn 
af~er tn~raven~r~~arty aamtnis~erea LabeLLed (D~ata ,D-teu )-enkephatin 
(12.5 ~i/JJ.L) in rat brain. Note that the LabeLLed $Ubstance aLso reached 
the extracerebrat space ot the ventricuLar system. 
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Withi.n 10 min, the whole ventricular system showed radioactivity 1 
including the central canal of the spinal cord (Pig.4). During this 
period of time a significant amount of labelled sUbstance coul.d be 
detected in the whole extracerebral ventricular system. (Pig .5). 
~g.4. Sag~ttat sect~on of the body and 
m~n 2 aftgr tntraventrtcutar D-ata ,D-Leu )enkephaLtn (12.5 ~~/~L). 
correspond.tng 
admi.nt.stra-tion 
Note that the 
penetrated t.nto the centraL canaL Of the sptnaL cora. 
autoradiogram, 10 
of tabeZ.Z..ed 
LabeLLed substance 
3.2. ~str£bution tn the pertventrtcuLar anato~caL regtons. 
After 1 min, radioactivity was observed in the ~1 of the left 
lateral ventricle, consisting of the septum, striatum and hippocampus 
(Pig.l). After z.s min the radioactive substance penetrated into the 
hippocampus and striatum as wel.l as into the wall of the third 
ventricle (Fig.2). Within ~0 min, ( 3B]DADL penetrated £rom the 
ventric~es ~nto the whole septum, parts of the corpus striatum and 
hippocampus and small parts of the corpus callosum and th~amus. 
Radioactivity was pronounced in the chorioidal plexus. 
EMG 
ECoG 
Hip 
Stri 
Sept 
Hip 
Stri 
Sept 
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CONTROl ~ OAOl. ivt. 5 ~g 
::::::~ -. ·""'"'"'..__,_.., .. ,~~ ~+I-H+,uumt+H-ti-H+1r~:W 
~ .,1,'1.1.1''·',1,,\\.1 I """"~···,, ..... ~.~~~"'-'~'1.~-t+·l··ldl.''"'"'~ 
t' ~~ 1il ~~~~~ L' ill 'I l ~rilooOj~ ....,jlp tV i~il:~()j A1 ~'!1"'~~lol>'~~ 
I 
6' 30' 60' 
' 
t l "~'' \.,. .••.••• ~"rrr•~~ .. "'~' u4•, 
.~ I100"V 
~g.5. ELec~romyogram (EMG), eLec~rocort~cogram (ECoG) and 
eLe~rophys~Log~caL responses of the h~ppocampus (h~p), striatum (str) and 
septum2(se~)5before ana after tntraventrtcuLar (t~) aamtntstrat~n Of (D-ata ,D-Leu) enkephaLtn (DADL, S~g/2 ~1). Note the sho~ onset of 
eptLepttc sptke acttvtty ana the Long-Lasttng and tntenstve effect of DADL 
tn the htppocampus. 
3.3. ELe~rophystotogtcaL recordtng 
The electrophysiol.ogical responses of the hippocampus, striatum and 
septum as we 11. as the ECoG and EMG show epi.l.eptic discharges and 
myoclonic contractions, within the time range of O.S-2 min after ivt 
administration of DADL. The latency times of the epilept'i.fo:rm 
muscular and EEG phenomena for each animal. are equaJ.. 
epileptic spikes are immediately followed by a MC. 
EEG or ECoG 
The epileptic spike activity in the septum and striatum are less 
intensive and short-lasting. The most intensive and long-lasting 
spiking, exceeding 30 min, is observed in the cortex and particularly 
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in the hippocampus ( Pi.g. 6). No differences are observed between the 
electrophysiological responses induced by ivt administration of 
equimolar doses of labelled and unlabelled DADL. 
3.4. ~fjUS~n of r~ct~v~ty tnto the bratn ttssue. 
Since the EMG and EEG recordings indicate that the epi.leptic phenomena 
induced by DADL (5 Mg,:ivt) appeared wi.thin J.-2 min, the depth of 
penetration o£ the radi.oactive substance into the brai.n tissue was 
measured over this period of time. 
The results indicate that the mean depth of penetration into the 
hippocampus, striatum and septum was about l.OO .um (Pig. 7 ) • After 30 
3 
and 60 min the diStribution of C B]DADL was £ound to be di.ffuse and 
difficult to evaluate. 
500 
400 
~ 
"" u f 300 
c 
• > 
E 
0 
.;: 
• 200 u 
c 
;J 
• i5 
100 
1 2! 5 10 20 30 
Time after ivt 3H-DADL administration (min) 
~~-7. speed Of dtffus~n of radtoacttve (D-a1a2 ,D-1eu5 )-enkepha1tn 
([ HJDADL, 12.5 ~/ML) tn the surroundtng pertven~rtcutar ttssue aj~er 
~ntraventri.cutar (~vt) aamtntstratton~ Note that utthtn 2.5 mtn (the onset 
pertoa for DADL tnaucea setzures) l HlDADL penetratea to a ae~h of about 
100 J..LITI. The vert"Lcat bars t.nat.cate SEM (n--4). 
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4. DISCUSSION 
Presumably, the radioactivity involves intact since the 
~ong-lasti.ng effect clearly suggests that the drug was neither metabolized 
nor rapidly cleared (Yaksh et aJ.., 1982). 
Tritium labelled DADL reached all parts of the ventricular system, 
including the extracerebral U.quor space, within 10 min after i.vt 
administration. The cerebrospinal fl.uid leaves the ventricular system in 
the vicinity of the fourth ventricle through apertures in the posterior 
medulla.cy velum (zeman and Innes, 1963 ), which might explain why the 
extracerebral radioactivity is more pronounced in the posterior sections. 
The time course of distribution of ( 3H]DADL within the ventricular system 
is consistent ~th the stream pattern of cerebrospinal fluid ~thin the 
ventricles. The 3a-Labelled DADL also penetrated rapidly into the 
periventricular tissue. The brain regions bordering the lateral ventricles 
are the striatum., septwn and hippocampus. Penetration of the radioactive 
sUbstance into these anatom1cal regions occured to a depth of about SD-100 
J.UD. during the first 2.5 mi.n after ivt administration. This period of time 
coincides wi. th the appearance of epileptic discharges in the EEG and the 
EMG. The shortest onset period and the most pronounced and long-lasting 
epileptic discharges in the EEG were observed in the hippocampus and 
cortex. Therefore, it can be suggested that the hippocampus is the 
anatomical regions associated wi.th the initiation of the seizure phenomena, 
after ivt injection of enkephalins. 
In literature it is suggested that endorphins and particularly DADL, exert 
their convulsant actions through activation of S opiate receptors (Ozoljic 
and vd Poel-Beisterkamp, 1.982). The striatum, septum and some parts of the 
hippocampus contain high densities of 5 receptors (Goodman et al., 1980; 
Duka et al., 1981). FUrthermore, the hippocampus and the striatum do have 
the lowest threshold for excitation (Cowan et al., 1979). 
It is suggested that the short onset of epileptic phenomena, after ivt 
administration of enkephalins or enkephalin analogs, is likely to be due to 
the activation of 5 opiate receptors, localized within the first 100 ~ of 
the periventricular tissue of the hippocampus. 
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CHAPTER VI. 
T8E EFFECTS OF SEL.BCT!VE 1J. ana 5 OPIATE AGONIST$ AND ANTAGONISTS ON 
EP!LEPTOGENIC POTENTIALS IN ANAESTHETIZED AND FREE-MOVING RATS 
SUMMARY 
(EEG) and eLect;romyographtc (EMG) 
free-movtng rats$ the eptLe~ogentc 
~htch setecttveLy sttmuLate ~ and s 
By us~ng e~ec~roencephaLograph~c 
recora~ngs Ln anaesthet~zed and 
properttes of 'tlJO opt.ot.a peptt,d.es, 
optate rece~rs, respecttvety 
1-nves-tt.gated. In addttt.on, l.)e 
recentLy synthestzea setecttve 
(ICI 154,129 and ICI 174,864). 
morphtcepttn and DSTLE, ~ere 
aLso ezamtned the effects Of t;uo 
antagontsts of the 8-optotd receptor 
The S recept;or pepttde (DSTC..F::, 4.6-18.5 nmot., t.v't) proaucea a 
aose-reLated t.ncrease of myoc~ntc contracttons (MC) wtth eptt.e~tc 
atscharges tn anaesthettzea rats ana severe Qet aog shakes, Mtth 
occasi.onaZ.Z.y fat.Z.t.ng dor.m, t.n free-movtng an:tmaZ.s. Morphtcept;tn, a 
spectftc 1J. optate agontst, used tn equtmoZ.ar doses and under the same 
ezpertmentaz. condttt.ons, had a stgntftcantz.y Less pronounced effect on 
the number of MC and eptZ.ept;tform BEG phenomena but tnhtbttea the 
DSTLE-tnaucea MC t.n a dose-retat:ed manner. DSTLE (18.6 nmoZ.) tnject;ed. 
tn ~he ~ area of ~he htppocampus$ a regton ~t~h a nearZ.y equaL 
ats~rtbu~ton of ~ and s optate receptors$ tnaucea eptLepttc atscnarges 
tn anaesthettzea and jree-movtng ra~s$ ~htLe an equtmoLar aose of 
morphtcep~tn had no stgntftcan~ effect. ~rtments ~t~h ICI 154,129 
and ICI 174,864 reveaLed that they antagontzed the eptLe~gentc 
ejjec~s of DSTLE. For thts purpose ICI 154,129 ~as needed tn a htgh 
concentra~ton, ~htch tnatcated ~he z.o~ potency Of thts substance. 
It ts sugges~ed th~ the eptZ.epttform acttvtty of optotd pe~taes ts 
matnLy aue to an ac~tvatton of S optate receptors tn the centraL 
nervous system. 
l. INTROOOCTION 
The concept of multiple opiate receptors (Lord et aL $ 1977; 
Martin$ 1981) might explain the various pharmacological. effects of 
opiate alkaloids and opiate peptides. In literature, it :is suggested 
that the analgesic action of opiates may be mediated by p. receptors 
(Urea et al .• 1977), while the epileptic effects of opiates are 
proposed to emerge from the s opiate receptor sti.mu·lation ( Prenk et 
However, other authors suggest that opioid-induced al., 1978). 
excitatory responses are predominantly mediated by p. receptors 
(Gahwi.ler and Maurer, 1981). 
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In previous studies Dzoljic ( 1982) demonstrated that myoclonic seizure 
phenomena and epileptic spikes in the 
induced by ( D-ala 2 , D-leu 5 )enkephalin and 
electroencephalogram ( EEG), 
other endopioids after 
intraventricular ( ivt) administration are probably mediated by 5 opiate 
receptors in the rat brai.n. The target area of this acti.on seems to be 
the limbic system (Henriksen et al., 1978), specifically the 
hippocampus (French and Siggins, 1980; Chapter V). The increase of 
neuronal excitability caused by opiates in the hippocampus is of 
particular interest, since opiates are found to depress neurons in 
other brain regions (Illes, 1982). 
Therefore, the aim of this study is to elucidate further the role of 
the ~ and 5 opiate receptors in the endorphin-induced neuronal 
activity, particularly in the hippocampus. For the experiments we used 
specific ligands, such as morphiceptin, which shows high specificity 
for the p. opiate receptor (Chang et al., 1981; Zhang et al., 198.1; 
Chang et aJ.., 1.982) and 5 receptor peptide ( DSTLE), one of the most 
specific 5 agonists presently known (Gacel et al., 1980). The last 
substance shows no cross-reactivity with the p. receptor sites (David et 
al., 1982). Both substances were injected into the hippocampus and, 
for comparison, into the lateral ventricle. Studies with opiate 
antagonists, such as naloxone and nal.trexone, have revealed that these 
drugs exhibit selectivity for the p.-receptor over both the s- and 
K-subtypes (Magnan et al., 1982). However, the recently- described 
enkephali.n analogues ICI 154,129 (Shaw et al., 1982; Gormley et 
al., 1982) and ICI 174,864 (Cotton et al., 1984), which are supposed to 
be selective s opiate antagonists, were also used in these experiments. 
Since there is evidence for opiate-anaesthesia interactions (Urea and 
Liebeskind, 1979; Linseman, 1980 ) , the experiments were performed in 
anaesthetized and free-moving animals. 
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2 • MATERil\LS AND METEIODS 
2.1. Anaesthet~zed rats 
2.1..1. Intraventricular admi.nistrati.on (ivt) 
The method used in these experiments has been described previously 
(Ozoljic et a1., 1979). In brie£, male Wi.star rats (20Q-275 g) were 
anaestheti.zed by urethane (1..2 gjkg, i.p. ). A steel cannula for ivt 
injections (coordinates: AP -o.l mm, L +LS mm, a -2.0 mm from 
dura, with bregma 0) was implanted by means of a stereotaxic 
instrument. Intraventricular injections were made by a 5 ~1 
aami.l.ton syringe. The electrocorticogram (ECoG) between the frontal 
and parietal. electrodes was recorded by means of a polygraph (Grass 
model 7). The electromyogram (EMG) of spontaneous and drug-induced 
myoclonic contractions ( MC) of the submandibular muscl.es was 
recorded by the method of Sieger et al.. ( 1963 ) . 
The term ••spontaneous myoclonic contractions.. corresponds to the 
irregular muscle twitches with low frequency ( 1-3 twitches;min) and 
low amplitude (mostly lower then so J.LV), which are due to 
mastication or other oral activities persist~g even during complete 
anaesthesia. 'l'he number of MC, correlating with ECoG epileptic 
spikes ( Dzol.j ic et al., 1980), were counted within the first 15 min 
after ivt admi.nl.stration of the drug. The most intensive spiking 
was observed during this period of time. 
2. 1. 2 . Intrahippocampal administration ( ihp) 
A steel. cannula for ihp l.njections and an electrode for EEG 
recording, were ~planted stereotaxically in the CA2 area of the 
hippocampus (coordinates: AP +2.6 mm, L -2.6 mm., H -2.9 mm from 
dura, with bregma 0) (de Groot, 1972). The ECoG, the 
e lectroencephal.ographic responses ( EEG) of the hippocampaJ. area and 
the MC were recorded. The number of EEG spikes in the hippocampus, 
the ECoG spikes and the MC were counted within the first 15 min 
after drug administration. 
Only those anima.l.s, which after injections of marker dye at the end of 
the experiment revealed dye in the ventricle/hippocampus, were taken 
- 74 -
into consideration for statistical analysis. 
0 
Rectal temperature was maintained between 36. s and 37 • 5 C. 
2.2. Free~mov~ng rats 
2. 2 .1. Int:x:aveutx::icular admini.stration 
Male wistar rats ( 200-275 g) were prepared for EEG, ECoG and EMG 
recording under Hypno:rm ( Duphar) anaesthesia ( o. 4 ml/lOOg, s. c. ) • 
Silver screw electrodes were fixed into the bone overlying the 
frontal and parietal cortices. The EHG was recorded from the neck-
and submandibular muscles. A steel cannula for ivt .injections (same 
coordinates as in anaesthetized rats ) was implanted stereotaxicaJ..ly. 
2 • 2 • 2 • Intr;:aiiJobojiLI:J!!E!r>C'""IIIIl0:?i'"LLJ adlai.nist:J:atn 
For record:ing of the EEG responses of the hippocampus, an electrode 
was irop.lanted in the CAZ area. A steel cannula for ihp injections 
( same coordinates as in anaesthetized rats ) was implanted by means 
of a stereotaxic instrument. ECOG, EEG and MC of the submandibular-
and neck muscles were recorded. 
All rats were a.J.lowed at least a 7-day recovery period before the 
experiments started. A new hydraulic system provides the possibil.i ty 
of administration of drugs in unrestrained rats, with full. external. 
control. upon the rate of flow, frequency and volume of drug injection. 
This system consists of a microsyringe (max volume 8 ,uJ.) and a 
connector base. The cap of the microsyringe is divided by a rubber 
diaphragm into two parts. The upper part is attached to a 
polyethylene tube filled with hydraulic oil.. This tubing is used to 
connect the injection assembly with the injection machine microdriver. 
The microinjection system can he placed in the cavity of the connector 
base, which is cemented to the skulL In addition, the connector base 
is al.so used as a plug for maximaJ.. 7 electrode leads. Via the 
connector base, the rat was attached to the cable connector, for 
recording el.ectrographic responses. M1croinjections of the drug 
solution into the lateral. ventricle or hippocampus was achieved by 
turning the microdrive. 
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2.3. Statts'tt.cs 
statistical evaluation of drug-induced M.C, exceeding 100 J.LV and EEG 
spikes, exceeding 4:00p.V, was performed by the Mann-Whitney rr test. 
2.4. Drugs 
The synthetic peptide, morpht.ceptt.n (tyr-pro-phe-pro-NB2 , Peninsula 
Lab. ) , which i.s an amide derivate of 13-casomo:rphine-4 and the 
hexapeptide, s receptor actt.vattng peptt.ae (0-tyr-ser-gly-phe-leu-thr, 
DSTLE, Peninsula Lab. ) , were dissolved in artifical cerebrospinal 
fluid ( CSF). The substances and the control injections were in a 
volume of 1-2 p.1. (dose-range 4.65-74.2 nmol), administered ivt over 
5-10 sec. For i.hp administration a dose of 18. 6 nmol/0. 5 JLl. of the 
drugs was given. 
rcr 154,129, N,N-Bisallyl-tyr-gly-gly-$-(CH2s)-phe-leu-oH, was 
dissolved in CSF and injected ivt in a dose range of 18.6-74.4 nmol. 
ICI 174,864, N,N-diallyl-tyr-a.ib-ai.b-phe-.leu-QH (aib: 
a:-aminoi.sobutyric acid) was dissolved in CSP and injected ivt in a 
dose range of 2.2-37.2 nmol. 
CONTROL t DSTLE ( 18.6 nmol, ivtl 
-LEMG ----------------------------------~~~,1 ~141 t1 +t~1-H1~~~1+~1-~-+-+4 1 I 
R EMG ------~--+14lli'illl+Hi ll++lll-f411 -H-11 -++!I H-11 +il, 1-+1 +I, +---1, I II+, I ++++I I, I
5 :::ec I 100 JJ.V 
Fi-g. 1 • [.ef"t ( L) and ri-gh"t ( R) et.ect;romyogram (EMG of "the submandi-buLar 
muscLes) and eLectrocorti-cogram (ECOG) of an anaestheti-zed rat, before and 
after i-ntraventr~cut.ar (tvt;) aamtntetratton Of s receptor pepttae (DSTLE, 
18.6 nmot./1 ~t.). Note the short onset of eptt.epttc phenomena af"ter DSTLE 
1-n:jecti..on. 
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Ftg.2. MYoc~on~c con~r~tons (MC) recorded eLec~romyographtcaLLy tn 
anaesthettzea ( ___ ) ana tree-movtng (-~-) rats, after tntraventrtcuz..ar 
(Lvt) admtntstrat£on of cerebrosptna~ fLu~ (CSF, 2 ~1, ) fOLLoQed by 0 
receptor pepttae (Ill) or morp'htcepttn (A). VerttcaL Z..tne tnc:r:£.cates the 
number of MC, obtained durtng the first 15 mtn after tvt drug 
admtntstration. The hortzonta1 Ltne represents the different doses of s 
receptor pepttde or morphtceptf..n tn nmoL. Each potnt tndt.cates the mean 
vaLue of 8 experiments. Vert teal. bars denote SEM. Note the stgntjtcant 
tncrease of S receptor pepttae-tnduced MC, compared to the effects tnduced 
by morphtcepttn. 
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3. RESOLTS 
3.1. In~raven~r~cu~ar adm~n~s~ra~~n 
Hip 
In anaesthetl.zed rats, DSTLE (4.65-18.6 nmol) induced wi.thin o.s-1. 
min, an i.ntensi.ve and dose-related i.ncrease of MC of the submandibular 
muscles, associ.ated Wi.th epi.lepti.c discharges in the ECoG (Fig.l). 
Further increase of the dose (37.2 and 74.4 nmol) was ~ot followed by 
an increase of response (Fig. 2 ) . The most potent dose of DSTLE ( 18 . 6 
nmol) in inducing the MC, was chosen for further experiments. Simi.lar 
admini.stration of DSTLE ( 4.65-37.2 nmol, ivt) in free-moving animals 
induced a dose-related increase of ECoG epileptic sp~es and MC 
(Fig. 2). A high dose of DSTLE ( 37.2 nmol) induced additional severe 
wet dog shakes ( WDS), associated wi.th epileptic bursts :in the ECoG and 
"falling down" of the rat (Fig.3). ·The epileptic burst was followed 
by postictal ECoG depression for about 0.5-l min. Further increase of 
the dose (74.4 nmol.) appeared to be lethal in 3 out of s animals and 
was therefore not included in Fig.2. 
WDS 5 SEC 
Ff,g.3. EMG, ECoG ana h~ppocampa~ BEG (h~p) 3 m~n aft-er aam~n~s"tra~~on of S 
recept-or pep't~de (DSTLe, 20 ~g, ~vt-). The ep~~ep"t~c burs~ uas corre~a"ted 
u~~h ue"t aog shakes (WDS). Not-e "the sUbsequen-t pos"t~c"ta~ aepress~on of "the 
exc~t-a~ory ac~~v~~y. 
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Lower doses of morphiceptin (4.65-18.6 nmol.) injected in anaesthetized 
or free-mov~ng rats, induced neither MC nor ECoG epileptic sp1kes, 
while higher doses (37.2-74.4 nmol) resulted in a slight increase of 
MC and ECoG discharges (Fig.2). urethane facilitated the 
OSTLE-induced MC, within a certain dose-range (Fig.2). However, no 
significant differences could be observed after administration of 
different doses of morphiceptin in anaesthetized and free-moving 
animals 
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o 
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c 
0 anaesthetized rats 
m free moving rats 
C =control 
MO=morphiceptin 18.6 nmol 
DSTLE= o receptor peptide 
!8.6 nmol 
• 
DSTLE MO c DSTLE MO 
~g.4. Eff~s Of ~nZrah~ppocampa~ (CA2) inject~n of 5 recopzor peptide 
(DSTLE) and morphiceptin (MO) in anaesthetized ana free-moving 
rats. The verticaL Line tnatcates the number of epiLeptic discharges ~n 
~he CA2 htppocampaL area durtng ~he ftrs~ 15 mtn af~er admtnts~ra~ton of 
cere~rosptnaL fLutd (C, 2 ~L), s recep~or pep~tde (DSTLE, 18.6 nmoL) ana 
morphtcep~tn (18.6 nmoL). Ver~tcaL ~ars deno~e SEM (n=6). ~means 
stgntftcan~ dtfference ~t~h respec~ ~ con~roL (p<O.Ol). No~e ~he htgher 
number of spon~aneous eptLep~tc sptkes tn ~he CA2 area of ~he htppocampus 
tn ure~hane-anaes~he~tzed ra~s, compared zo ~he free-movtng antmaLs and ~he 
stgntftcan~ dtfferences tn tnductng EEG eptLep~tform phenomena ~e~~een ~he 
equtmoLar aoses of ~he ~ ana S opta~e recep~or agonts~s, compared ~ ~he 
con~roL. 
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3.2. In~ran~ppocampaL aam~nts~ra~~n 
DSTLE (1.8.6 nmol) administered in anaesthetized and free-moving rats, 
showed a pronounced increase of epileptic discharges in the 
hippocampal. EEG (CA2 area), ECoG and sUbmandibular MC, whi.J.e an 
equimolar dose of morphiceptin had no siqn~ficant effect on these 
parameters. 
hippocampal 
The difference between OSTLE and 
spiking is demonstrated in Fig. 4. 
morphiceptin on 
The number of 
DSTLE-induced neuronal. discharges (hippocampal or cortical spikes) 
were immediately followed by a same number of MC. Al.l these three 
excitatory phenomena gradually declined and disappeared within 3D-GO 
min. In free-moving animals, DSTLE i.nduced significantly less wet dog 
shake phenomena in comparison to ivt administered DSTLE. The 
hippocampal epileptic discharges induced by DSTLE were also 
facilitated by urethane anaesthesia (Fig.4). 
3.3. Pretrea~ment ~tth morphtcepttn 
K:::>rphicepti.n ( 9.3 and 18.6 nmol), aOm.i.nistered ivt in anaesthet:ized 
rats or ihp in anaesthetized and free-moving animals, 15 mi.n prior, 
significantly inhibited the number of MC and epileptiform discharges 
induced by DSTLE ( 18.6 nmol). The inhibitory effect of morphiceptin 
on DSTLE-:induced MC is demonstrated in Pig. 5. Pretreatment with 
morphiceptin (37.2 nmol) injected ivt in free-moving rats, 15 min 
prior, blocked the MC and wet dog shakes, induced by an equimolar dose 
of OSTLE. 
3.4. Pre~rea~men~ ~~~h 5 op~a~e an~agon~s~s 
ICI 154,129 injected 10 min prior, was effective in inhibiting the 
OSTLE (18.6 nmol)-induced epileptic phenomena only in high doses 
(46.5-74.4 nmol) (Table 1)- The antagonist caused initial spike 
activity :in the ECoG, but no MC, in the first 30 sec after 
applicati.on. 
Low doses (2.2-4.5 nmol) o£ ICI 174,864, injected 10 m:in prior, 
inhibited the intensity and duration o£ the MC and the correlated 
epileptic discharges in the ECoG, :induced by DSTLE (Table L). 
Admi.nistration of ICI 174,864 ( 9. 3-18.6 nmol) resu1ted in a depression 
of amplitude of the ECoG activity for over 2 hours. In this period of 
time DSTLE ( 18.6 nmol) did not induced any MC or epi.1eptic discharges 
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C =Control 
0= o receptor peptide 
(DSTLE, 18.6nmol) 
MO = morphiceptin (nmol) 
T 
MOC9.3l 
,-
M008.6l 
.. 
c 
• 
IT 
~g.S. lnteract~ns bet~n ~~rph~cept~n ana 5 recep~r pept~de in 
urethane-anaesthet~zea rats. The vert~caL L~ne tnatcates the number of 
etectromyograph~atLy recorded myoc~nic contra~tons (MC) obtained during 
the first 15 min after intraventricuLar (ivt) aamtntstratton of 
cerebrospinaL fLuid (2 ~L~ C) and DSTLE (18.6 nmoL). MOrphtcepttn (9.3 or 
18.6 nmoL) ~ ~ntsterea tvt 15 mtn before DSTLE. VerticaL bars aenote 
SEH (n--B). r means stgntjf..canmt. d:t.fference from DSTLE (p<O.OZ). Note t-he 
dose-reLated tnhtbitton of DSTLE-tnducea MC by morphtcepttn. 
EIIIIG 
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(Fig. 6). A high dose of this a.ntagon:ist ( 37.2 nmol) inhibited ECoG 
activity for at least 15 min and ECoG was practically without wave of 
spike acti.vi.ty ( "ECOG silence") and very weak for the next hour, while 
breathing was normal.. 
control 
DSTLE 
t 
I I I I I \ I \ \ I I I I 1 
ECoG ~~ 
control 30 
EIIIIG 
·~ ., ~ lit ~~ ·~ ~ 
sse;, I 100pV 
~g.6. EMG or ~he submandtbuLar muscLes ana the ECoG Detore and after 
~n~raventrtcu~ar administration of DSTLE (18.6 nmoL) and ICI 174,864 
(9.3 nmoL). Note tne aepresston of ampLttuae of tne ECOG tnaucea ~Y 
rcr 174,864. 
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Tab~e 1. ~oc~ontc con~r~tons correLa~ea ~t~h ECoG epiLeptic spikes 
(mean ± SEM) induced by intraventricuLar (t~) admtntstrat~n of the 5 
opiate agonist, DSTLE (18.6 nmoL) and after pretreatment Qtth different 
doses of the s optate antagonists, rcr 154,129 and rcr 174,864. The 
antagonists ~ere tnje~ea tvt 10 mtn pr~r to DSTLe. 
DSTLE (18.6 nmol, ivt) 
Pretreatment 
ICI ~54,129 (ivt) 
18.6 ru:nol 
37.2 nmol 
46.5 nmol 
74.4 runol 
ICI 174,864 (ivt) 
2.2 nmol 
4.5 nmol 
9.3 nmo1 
18.6 nmol 
37.2 nmol 
X± SEM 
193 ± 13 
183 • 25 
181 • 9 
117 ••• 
49 • 7' 
15 • 6• 
23 • 9' 
no DSTLE-induced MC 
no OSTLE-induced MC 
ECoG siJ.ence 
*: significant difference compared to DSTLE-induced MC (P<O.OOl, n=6) 
4. DISCUSSION 
The specific 5 opiate receptor agonist, DSTLE, admi.n:istered ivt, induced a 
dose-related increase of MC and EEG epileptiform discharges in 
anaesthetized and free-moving rats. 
Thi.S is in contrast to the specific J.L agonist, morphiceptin, which was 
significantly less potent in inducing MC, unless high doses, compared to 
the effective doses of DSTLE, were administered. This indicates that J.L 
receptors are probably not involved in the seizure phenomena. Furthermore, 
low doses, in comparison with the effective dose of DSTLE, of the specific 
s opiate receptor antagonist ICI ~74,864 inhibited the epileptic phenomena 
induced by DSTLE. This is consistent with the suggestion that B opiate 
receptors are involved in the endorphin-induced seizures (Frenk et 
al., 1978; Dzoljic, 1982; Dzoljic and vd Poel-Heisterkamp, 1982). Prom 
autoradiographic studies and EEG recordings, we suggested that the 
hippocampus can be held responsible for the triggering of endorphin-induced 
- 83 -
seizure phenomena (Chapter V). 'rhl.s is favoured by the demonstration of a 
relatively high density of opiate receptors in the hippocampus, 
specifically in the pyramidal cell. layer ( MeWach and Maayani, 1980) and 
enkephal.i.n--containing fiber-systems in this brain region (HOkfelt et 
al.., 1977; Rossier and Bloom, 1980). Furthermore, it is known that 
opioids excite the hippocampal pyr~dal neurons (ZieglganSberger et 
al., 1981), which is in contrast to the opioid-induced depression of 
neurons in other brain regions (Illes, 1982). Therefore, we decided to 
adm1nister the selective opiate receptor agonists in the hippocampus as 
well. The CA2 area of the hippocampus was selected because of the highest 
density of opiate binding sites ( Meibach and Maayani., 1980) and the 
reLatively equal distribution of ~ and 5 opiate receptors, in comparison to 
other hippocampal regions ( OUka et al.., 1981). 
Local. administration of DSTLE induced a significant increase of epile~ic 
discharges in the CA2 area, whi.le an equi.molar dose of morphice~i.n had no 
pronounced effect. This fact supports the idea of the involvement of 6 
opiate receptors in the generation of epileptiform. phenomena. Pretreatment 
with morphiceptin, inhibited the stimulatory 6 receptor mediated effect of 
DSTLE in anaesthetized and free-moving rats. Thi.s might be due to the fact 
that morphicepti.n acts as a partial agon:ist for the 6 receptor system (Day 
et al., 1.981.; Chang et al., 1982). Increase of MC, in this study, 
following administration of high doses of morphicepti.n, i.s probably also a 
result of the 6 opiate receptor stimulation. However, stimulation of the J.L 
opiate receptors by morphicepti.n, bad a pronounced anticonvulsive effect, 
which supports the hypothesis about the proconvulsant 6 receptors and 
anticonvulsant J.L opiate receptors (Ozoljic, 1982). 
Pretreatment with high doses of ICI 154,1.29 resulted in an inhibition of 
the M.C and spike activity induced by the 5 agonist. These findings are 
consistent with those of Tortella and coworkers ( 1984), who demonstrated 
that ICI 154,129 raises the seizure threshold in rats but at high doses 
exhibit p. agonist properties. The low potency of this substance at the 6 
receptor (COtton et al., 1984) has limited its value as a pharmacological 
tool and the high doses needed to inhibit the DSTLE-induced epileptic 
phenomena might as well be a result of an activation of the anticonvulsive 
p. opiate receptors, instead of a specific antagonism at the S receptor 
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site. In contrary, low doses of ICI 174,864 were effective in bloCking the 
epileptic phenomena, while high doses resulted in a complete depression of 
ECoG acti.vl.ty. These results indicate that this substance is 
pharmacologically a more potent s antagonist compared to ICI 154,129. 
Intraventricular administration of DSTLE in free-moving an~ls, resulted 
:i.n severe wet dog shakes, falling down and an excited behaviour. In 
contrary, a local injection of the 8 agonist in the CA2 area of the 
hippocampus, induced less or no wet dog shakes. This difference in 
activity mi.ght be due to the fact that after ivt administration of DSTLE, a 
higher number of 8 opiate receptors are activated. 
Related to the interactions with anaesthesia, it was observed that urethane 
facilitated the DSTLE-induced MC. The reason for this stimulatory effect 
of urethane on enkephalin effects is not clear, but a possibl.e additional. 
rel.ease of endorphins during anaesthesia (Berkowitz et al.., 1.976) might be 
one of the explanations. other data indicate that the effects of morphine 
can either be inhibited or stimul.ated in anaesthetized rats in comparison 
to free-moving animal.s (Urea and Liebeskind, 1979; Linseman, 1980). This 
study demonstrates that the effects of opioid peptides can also be 
significantly moduLated by urethane anaesthesia, which indicates the 
necessity of paral.l.el study in free-moving animals and which has to be 
taken into account in clinical circumstances, when administering 
opiate-like subStances to post-operative patients. 
In concl.usion, this study with rel.ativel.y specific opiate agonists and 
antagonists suggests that the epil.eptiform activity of opioid peptides is 
mainly due to an activation of s opiate receptors. 
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CHAPTER VII. 
METABOLIC RATE IN DIFFERENT RAT BRA!N AREAS DURING SEIZURES INDUCED BY 
A SPECIFIC DELTA OPIATE RECEPTOR AGONIST 
SUMMARY 
The gtucose u~tttza~~n aurtng spectftc14s optate agontst-tnducea 
epttepttform phenomena, determtnea by the [ C]2-de~gtucose techntque 
(2-DG) ~as examtnea tn v~us rat bratn areas at attferent ttme 
tntervats. The peak tn EEG sptktng response ana the most tntenstve 
2-DG uptake occurea 5 mtn after tvt admtntstrat~n of the s opta~ 
receptor agontst. The most pronounced 2-DG uptake at thts ttme 
tntervat couta be observed tn the subtcutum, tnctuatng the CAl 
h"L.ppocampat area, tront;at corte::r and cen-trat amygdaLa. A generaL 
aecrease Of gLucose consumptUm, comparea to controt vatues, uas 
observed after 10 mtn, tn att regtons tJtth ezceptton of the subtcutum. 
Stnce functtonat acttvtty ana 2-DG uptake ~ere corre~a~ea, ~ sugges~ 
that the su~~cu1um and/or CAl area, are proba~~y the ~ra£n reg~ns most 
tnvo1ved tn the enkepha1tn-tnauced ept1eptttorm phenomena. 
~. INTRODUCI'ION 
There is evidence that endorphins may pLay a role in epileptogenesis 
(urea et al..l977; Dzol.jic and vd Poel-He:isterk.amp, 1.982). The target 
area of this action seems to be the lilxibic system ( aenrikSen et 
al.., 1982; Ill.es, 1982), and specifical.l.y the hippocampus (French and. 
Siggins, 1980, Chapters v and VI). The increase of neuronal. excitation 
caused by opiates in the hippocampal area is of particular interest 
since opiates have been found to depress neurons in other brain regions 
(Il.l.es, 1982). 
Because functional activity and energy metabolism appear to be closely 
related in the nervous system (Sokoloff, 1977), local. al.terations in 
glucose util.ization accompany and reflect local changes in neuronal. 
activity in the rat brain (Kennedy et al.., 1975). Studies using the 
[ 14c]2-deoxyglucose histochemistry with intracerebroventricular (ivt) 
13-endorphin injection, show the most dramatically enhanced metabolic 
activity in the ventral hippocampus and the entorhinal cortex, thus 
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favouring these structures as the possible sites of origin for the 
drug-:induced epileptiform. activity (Henriksen et al., 1982). 
osi.ng a modification of Sokoloff•s technique (Meiba.ch et al., 1980) and 
a method for isolated removal of brain ti.ssue (Palkovits, 1.973}, we 
selected some rat brain areas, which from: l.iterature and our previous 
studies appeared to be i.nvol.ved in the neuronal excitability after ivt 
admi.ni.Stration of enkephal.ins (Frenk et al., 1978; French and Siggins, 
1980; Chapters V and VI). In the present study we utilized these 
methods to ascertain what changes occur in the metabol.ic rates of 
different regions ~n the CNS, during opioid-induced seizures. 
Therefore, we compared the glucose uptake in some rat brain areas, in 
function of time, during a state of normal neuronal excitability and 
during 5 receptor peptide ( Gacel et aL, ~9SO) (DSTLE)-induced 
epilepsy. DSTLE, as an 8 opiate recepto:r; agonist is selected since the 
epileptiform phenomena are proposed to emerge from 8 opiate receptor 
stimulation (Chapter VI) and probably not from the activation of p. 
receptors (Frenk et al., 1978; Snead and Bearden, 1980). 
2. MATERIALS AND METHODS 
2.1. 2-~oxyg~ucose uptake. 
24 Male Wistar rats ( 175-200 g) were anaesthetized by Hypnorm 
(fluanison/fentanyl. base, Duphar, 0.4 m.l/100 g, s.c. ). A steel 
cannula for ivt injections (coordinates: AP -o.l mm, L -1.5 mm, 
a: -2.0 mm from dura, with bregma O) (KOnig and KlippeJ., 1963) was 
implanted stereotaxically. Each canulla implantation was checked with 
a positive passage of artifical cerebrospinal flui.d (CSF) into the 
ventricle. All rats were allowed a recovery period of at least 7 
days. Intraventricular injections were made by a 5 ~l Hamilton 
syringe. 
The 2-deoxyglucose ( 2-DG) experiments were performed according to the 
method of Meibach et al. ( 1980). 
The experimental. paradigm consisted of ivt injections of DSTLE ( 10 
JA.9/2JJ.l), 0, 2. 5, 5 and 10 min preceding the intravenous adml.nistration 
of 2-D (10 ~Ci/lOOg). Control animals received CSP (2 J,Ll., ivt) 
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instead of DSTLE. 
30 mi.n after the 2-DG injection, the cannula was wi.thdrawn and the 
an~ decapitated. The skull was opened, the brain careful.ly 
0 
removed, frozen in dry ice and stored at -70 C before sectioning. 
The brain was cut in 300 J.Un. serial sections in a cryostat, maintained 
0 
at -20 C. Brai.n nuclei were punched wi.th hollow needles, according to 
Pa.J.kovits ( 1973). Nine individual brain regions were taken from each 
rat: frontal cortex ( FC), parietal cortex (PC), subicul.um, incl.ud:ing 
CAl ( s), dentate gyrus (GO), CA3 hippocampal. area, central amygdal.oid 
nucleus ( ac), cortical. amygdaloid nucleus ( aco), l.ateral. septal 
nucleus ( SL) and the nucleus parafascicularis thal.am:i ( pf) . 
Tissue pellets were homogenized in 100 JLl of distilled water. An 
aliquot of 10 p.l was taken in duplicate for the measurements of 
proteins (Lowry et al.., 1951). 
Radioactivity was determined of two al.iquots of 40 p.l. from the 
homogenate by l~quid scintillation counting. Results are given in 
pmol/100 ~g protein. 
stati.stica1 evaluation was performed by the Mann-Whitney a-test. 
z.z. ~e~roencepha1ograph~c recora~ng 
Six ma.J.e rats (Wi.star strain, 175-200 g) were anaesthetized by 
urethane ( 1.2 gjkg, Lp. ). A tracheal canulla was inserted. A steel 
lOcannula for ivt injections and electrodes into the Subiculum 
(AP +3.6 mm, L +0.4 mm, H -3.1. mm from dura), lateral septum 
( AP + l. .1. mm, r .. + 1 • z rt'I!Xl, R -4.6 mm from dura) and central amygdala 
(AP +0.3 mm., L +4.1. mm, H -7.1 mm from dura with bregma 0) (Konig and 
Klippel, 1.963) were implanted stereotaxically. In addition the 
electrocort~cogram of the frontal and parietal cortices was recorded 
by means of a polygraph Grass model 7. The regions were selected on 
basis of the maximal and minimal metabolic rate changes -during 
DSTLE-induced epilepsy. Rectal temperature was maintained between 
36.5 and 37.5 °C with a warm light. After the experiment, the 
placement of the electrodes was checked histologically. 
2.3. Drugs 
2-[l.-14c]Deoxy-D-glucose (2-DG; New England Nuclear). 
2-DG, Sl..J. mCi/mmol, suspended in ethanol-water (9:1) was placed in a 
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vial and the ethanol medium slowly evaporated with a gentle stream of 
gaseous nitrogen. The isotope was diluted in sterile 0.9% saline (250 
IJ.C'i/2. 5 m.1). The solution was injected intravenously. 
s receptor peptide. 
(D-tyr-ser-gly-phe-leu-thr, DSTLE, Peni.nsuJ.a Lal:>.) was dissolved in 
CSP ( 10 J,J.g/2 J.Ll) and a.d:ministered intraventricularly. 
3. RESULTS 
3.1. 2-DG up~ake. 
Simultaneous injection of DSTLE ( 1.0 J.Ll/2 JJ.g, ivt) and 2-DG ( 10 p.Ci/100 
g, L v. ) resulted in an increase of 2-DG uptake in the frontal cortex, 
subiculumfCAl area and the corti.cal. amygdala, compared to the 
controls, which received CSF, z JJ.l (Table l, "0 min"). In the other 
selected brain regions, such as the central amygdal.a, parietal cortex, 
lateral. septal. nucleus, gyrus dentatus, CA3 area and the 
n. parafascicularis thal.am:i, no differences in the glucose uptake 
could be observed. DSTLE administration, 2 . 5 min prior to the 2-DG 
pulse resulted in a general increase of the uptake in all regions, 
most pronounced in the frontal. cortex, subiculum/CAl. and the cortical 
amygdala. Less pronounced uptake of 2-0G occured in the parietal 
cortex, dentate gyrus and CA3. No significant :i.ncrease could be 
detected 1n the lateral septum, central amygdala and the 
parafascicular nucleus. DSTLE injection, preceding by 5 min, the 2-DG 
administration, induced a further significant increase of glucose 
utilization in the frontal cortex, subiculum and central amygdala. 
However, a tendency for a decrease in 2-DG uptake could al.ready be 
observed in al.l other areas with exception of CA3 (Table 1). 
10 min after the DSTLE injection, glucose utilization decreased to 
control values in aJ.l brain regions with exception of the subiculum. 
In the n.parafascicularis and the lateral septal nucleus, the 2-0G 
uptake was not significantly affected by DSTLE. Because of this 
general decrease after ·10 min, no further experiments, with longer 
time intervals between the DSTLE and the 2-DG injection, were carried 
out. 
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T~Le 1.Mean vaLues +S.E.M. of 2-DG uptake. 
f C)2-deoxyglucose (2-DG, 10 ,u.Ci/100 g, Lv.) uptake in various rat brain 
areas of control animals (cerebrospinal fluid, csF, 2 JJ.l, ivt) and at 
different time intervals after s receptor peptide (DSTLE, 1.0 1J.9/2 ,u.l, ivt) 
administration. Note the significant increase of the 2-DG uptake after 
OSTLE admi.nistration in the frontal cortex ( FC), subiculum, incl.uding CAl. 
( s) and central and cortical amygdala ( ac, aco) . A less pronounced 
increase of the 2-DG uptake can be observed in the dentate gyrus (GO), CA3 
hippocampal region and parietal cortex (PC ) . The 2-DG uptake in the 
lateral. se!)tal nucleus (SL) and n.parafascicularis thalami (pf) was not 
significantly changed by DSTLE injection. 10 min after DSTLE application a 
general decrease of the 2-DG uptake occurs. Significant difference 
compared to controls: ** p<O.OOl. and * p<0.05. 
Time inrervals berween DSTLE and 2-DG injecrion 
Brain area CSF 
Conrrols Omin 2.5 min 5 min 10 min 
FC 22.7 ± 2.5 30.0 ± 1.2** 34.0 ± 4.6** 37.4 ± 2.9** 25.9 ± 2.3 
PC 25.3 ± 4.6 24.1 ± 3.6 32.2 ± 3.8* 24.5 ± 2.8 24.9 ± 2.9 
s 17.0 ± 1.7 22.5 ± 1.5* 29.6±2.1** 46.8 ± 2.2** 26.1 ± 1.6*' 
GD 17.3±0.9 16.7 ± 1.3 24.5 ± 2.2* 20.3 ± 2.8 19.9 ± 0.3 
CA3 18.4 ± 3.9 20.4 ± 2.0 25.5 ± 3.0* 26.9 ± 6.7 20.7 ± 0.7 
ac 16.6 ± 2.6 16.2 ± 1.5 20.3 ± 1.4 30.8 ± 2.6** 14.2 ± 1.6 
a co 23.7 ± 4.6 31.4±1.1** 31.7 ± 4.3** 29.2 ± 3.2 20.1±1.8 
SL 18.6±2.7 16.6 ± 1.7 22.1 ±2.9 14.9 ± 9.6 15.9 ± 3.5 
pf 20.5 ± 1.8 21.8 ± 0.8 26.1 ±3.9 20.0 ± 7.9 21.2 ± 2.9 
3.2. ~ec~roencephatographtc (EEG) recoratng. 
During the EEG recordings in the frontal. and parietal cortices, the 
subiculum, the central amygdala and the lateral septum, an onset 
period for the OSTLE-induoed epileptic discharges of about 30 s was 
observed in the subiculum (Pig.l). These excitatory phenomena 
appeared a few seconds later 
frontal/parietal cortex. 
in the central amygdala and 
In all these regions, with exception of the lateral septum, the 
intensity of the spiking exceeded 400 ~V within 1 ~n'after DSTLE 
administration. aowever, the most intensive and long-laSting spiking 
was observed in the subiculum and central amygdala. 
- 92 -
'-" .c_"""""-__ ..., __ t,osn _ _,'r-·'vt..;;:·"';;,..:;:.._,_,-t...,...,...,._,,..l>i"_ ,•..,...,._...,.,..,.. .'_•·----~ ;,..;:._ __ _ 
CEA--- _,..__.,...,..,..,.,..I ......... ~ ........ ,..,l;,.j..,\+l++i I f<HH1i'lill•l 
""---- lk • ;bir~~oc.u-~Mii ltj<Lj•I\LI,/[~"~P!Liil41\.Jl\~il~lf 1 ·~\>1111~• ~trl\'41...........,._~ 
"'----
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~g.!. ELec~roencephaLograph~c responses of ~he La~eraL 
sep~um (LS), cen~raL amygdaLa (CEA), subtcutum (S), parte~aL cor~ex (PC) 
and tron~aL cor~ex (FC), before and af~er ~n~raven~rtcuLar (tv$) 
admtnts~rat~n of 5 recep~r pepttde (DSTLE). Note the unequaL sptktng 
acttvtty tn the var~us bratn regtons at the different ttme tntervaLs. 
4. DISCUSSION. 
The EEG responses and the results of the 2-DG uptake in this study, 
indicate that the frontal cortex, central amygdala and the sUbiculum/~ 
region, are the main areas involved in the DSTLE-induced epileptic 
phenomena. These results are generally in accordance with the [ 14c]2-00 
autoradiographic study of Henriksen et al. (l982), who demonstrated a 
marked l.ncrease of 2-DG uptake in the amygdalo-hippocampal area after ivt 
adndnistration of ,t3-endorphin. Of particular interest is the subiculum, 
which in this study, included the pyramidal. cell layer of the CAl. In this 
area the intensity and duration of the l.ncreased 2-DG uptake was most 
pronounced. The electrophysiological responses of this hippocampal region 
Showed the shortest onset of DSTLE-l.nduced epileptifo~ discharges as well 
as long-lasting EEG spike activity. 
Based on electrophysiological studies, it is suggested that opiate evoked 
epileptiform activity in the l~ic system arises from pyramidal cell 
activity in the hippocampal 
Zieglgansberger et al., ~979). 
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£ormat1.on {French and Siggl.ns, ~980; 
Thus, the hippocampus and particularly the 
subiculum and/or CAl area are the probable trigger-zones for seizures 
induced by an ivt adm:in'istration of enk.ephalins. It is possible that these 
regions pl.ay an important role i.n the opiate-modulated neuronal. 
excitability also in physiological and/or pathological conditions ~ 
humans. other hippocampal areas, like CA3 and the dentate gyrus, showed 
onl.y a moderate and gradually increase of the 2-DG uptake after DSTLE 
injection. Although the uptake was si.gnifi.cant, it was less intensive 
compared to the glucose utilization in the subicular region during the 
epileptic phenomena. 
In the l.ateral septum, we di.d not find an increase of 2-DG uptake after 
DSTLE application, which is in contrast to the data of Henriksen et 
al. (1982). This controversy ~ght be due to the different act~vities of 
~ndorphin and the erikepha1in-analogue, the S opiate receptor agonist, 
OSTLE. However, of particuJ.ar importance is the fact that in this study 
the lower level of energy metabolism correlated with the short-lasting and 
less intensive epileptic discharges in the EEG, compared to the responses 
of other brain areas. 
Increase of glucose utilization in the cortical and central nucleus of the 
amygdaLa might be due to an activation of the central nucleus following 
stimulation of different parts of the subiculum. Pathways connecting these 
structures have been demonstrated by watson et al. ( 1983). Furthermore, 
the central nucleus of the amygdala is rich in etikephalin-containing fiber 
systems and opiate receptors (Meibach and Maayani, 1980). 'rhe peak of the 
2-DG uptake in the cortical amygdaloid nucleus occured at about 2.5 min 
after OSTLE administration. However, for the central nucleus the peak 
appeared z.s min later. Possil:>ly, the activation pathway runs from the 
cortical to the central nucleus of the amygdala. 
The increase of glucose uptake in the frontal cortex after DSTLE 
application is probably a reflexion of the excitation of the hippocampal 
area. Namely, using the 2-DG technique, pronounced labelling of the 
frontal cortex following elicitation of seizures in the hippocampus has 
been demonstrated (Watson et al., 1983). 
Based on these results, we suggest that the hippocampal formation but 
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parti.cularl.y the subicu1um and/or CA1 are the probabl.e trigger zones for 
seizures induced by ivt administration of endorphins. FUrthermore, the 
results indicate a strong relationship between the electrophysiological 
recordings, the functional activities and glucose utilization/energy 
metabolism in different rat :brain areas, which also supports our earlier 
observations concerning the brain regions involved in the endopioid-induced 
epilepsy (Chapters v, VI ) . 
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CHAPTER VIII. 
REGIONAL CEREBRAL BLOOD FWW DURING ENKEPBALIN- INDUCED SEIZURES IN THE 
FIAT 
SUmmary 
B~ f~~ ae~e~nea by ~he r~~ve ~crosphere ~echn~que ~ng 
e~Le~~form se~zures tnauced by D-~yr-ser-gty-phe-teu-thr (DSTLE), a 
spectftc 5 optate agontst, ~as examtnea tn dtfferent rat bratn areas at 
vartous ttme tntervats. 
An tncrease tn b~ fLo~ to the htppocampus and the bratn stem ~as 
observea 2.5 mtn after the admtntstratton Of DSTLE tn~ the Left 
LateraL ventrtcLe. An addtttonaL fLo~ tncrease occured tn the strtatum 
and cerebeLLum 2.5 mtn Later (5 mtn after the tnje~ton), at ~htch ttme 
both the neuraL ana vascuz.ar effec-ts o:t the arug ZJere most markea. Ten 
mtn after the arug aamtntstratton, cerebraL bLood :fLo~ tn aLL regtons, 
exce~ the htppocampus, returned to the respecttve basez.tne vaLues. 
~nee the ttme course ana the magnttuae o:t :tuncttonaz. acttvtty and 
bLooa f~o~ tn £he htppocampus sho~ a gooa corre~a~ton, t~ ts suggested 
~ha~ ~nts ~ratn regton may pLay an essen~tat rote tn trtggertng and 
matntatntng ~he enkepha~tn-tnaucea ept~ep~tc phenomena. 
1. INTRODUCTION. 
Accumulat1ng ev~dence suggests that the epileptiform activity of the 
opioid peptides is ma~nly due to an activation of the s opiate 
receptors (Chapter VI ) • several studies have demonstrated that while 
the opioid peptides J.nhil:>it neuronal firing in most brain areas (Illes, 
1982) they excite the hippocampa.J. pyramidal cells ( Zieglgansberger et 
al., 1979). Indeed, using the 2-deoxyglucose method (Sokoloff, 1977), 
we showed that intraventr~cular (ivt) ~njections of 
D-tyr-ser-gly-pbe-thr ( DSTLE, Chapter VII), a peptide with specific s 
opiate receptor agonist activity (Gacel. et al., 1980 ), and of 
13-endorpbin (Henriksen et al., 1982), significantly increase the 
metabolic activity of the hippocampal area, thus favouring this 
structure as the possible site of origin of the epileptiform activity 
(Henriksen et al., 1982; Chapter VII). 
Changes in neuronal activity are also reflected by alterations in local. 
cerebral blood flow ( LCBF). 
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In patients with focal cortical epilepsy a marked increase in blood 
flow occurs during seizures in areas presumed to participate in the 
seizure activity (Meyer et al., ~966; aougaard et al.., 1976). 
Increases in cerebral metabolism concomitant with blood flow changes, 
have al.so been frequently demonstrated in experilnental ani.maJ.s, during 
epileptic seizures induced by agents, such as pentylenetetrazol and by 
electroconvulsive stimulation (Plum et al., 1968; Siesjo et 
al.., 1980). 
Therefore, in this study, we measured the blood flow in different areas 
of the rat brai.n before and during epi.l.eptic seizures induced by 8 
receptor peptide ( DSTLE). The measurements have been made at such time 
intervals at which enhanced neuronal excitability and metabol:i.sm was 
demonstrated (Chapter VII). 
2. MATERIALS AND METHODS. 
2.1. General.. 
Male albino rats of Wistar strai.n, weighi.ng 30D-350 g, were obtai.ned 
from TNO Central Breeding Institute, zeist, The Netherlands. 
The anima.l.s were anaesthet:i.zed with urethane (1..2 gjkg, i.p. ). The 
trachea was cannulated but the animals were allowed to breath 
spontaneously. A steel cannula was implanted stereotaxically into the 
left lateral ventrJ.cJ.e (coordinates: AP -o .1. mm.. L + l.. 5 mm, a: - J.. 7 mm. 
from dura with bregma O) (KOnig and KJ.ippel., 1963) for 
intraventricular ( ivt) injections. The position of the cannula was 
checked with an unrestricted passage of artifical cerebrospinal fluid 
(CSP) into the ventricle. A 5 J.Ll Hamilton syringe was used for the 
ivt injections. 
SUbsequently, the left femoral artery was cannulated with an 
appropriate polyvinyl catheter to record arterial blood pressure with 
a Statham P 23AC transducer on a model 7 Grass polygraph. The same 
catheter was used for withdrawing arterial blood samples. Blood gases 
were measured with an ABL--2 (Radiometer, Copenhagen). 
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2.2. RegtonaL cerebraL bLooa fLo~ measuremen~s. 
The radioactive microsphere technique was used for the measurements of 
regional. cerebral blood flows in rats (McDevitt and Nies, 1976). The 
left ventric1e of the heart was cannulated via the right common 
carotid artery with a thin polyvinyl. catheter. A suspension of about 
200.000 spheres (J.S :t2[SD] J.Llll; NEN, Dre:ieich; West-Germany), 
labelled with either 141ce, 103Ru, 113sn or 95Nb, in 0.2 ~ of 0.9% 
saline contain~ng a drop of Tween 80, was slowly injected via the 
cannula into the heart. 
starting 5 sec before the injection of the microspheres, arterial. 
blood was withdrawn (rate: 0.5 m.l/min) from the left femoral. artery 
over a period of 90 sec for determining the radioactivity. 
At the end of each experiment, the animal was ki1led by decapitation. 
The skull was opened and the brain ca.l;'efully removed and dissected 
into the fo1lowi.ng areas: the cerebral. cortex, striatum, hippocampus 
and thalamus of both the left and right sides, the septo-hypothalamic 
area, cerebel.l.um and brain stem. The various tissue samples were 
weighed and subsequently pl.aced in pl.astic vials. The radioactivity 
in the tissues and arterial. blood samples was counted for 10 min in a 
y-sci.ntill.ation counter (Packard, model 5986) equipped with a 
multichannel analyzer using suitable windows for discrim.i.nating the 
different isotopes used (Saxena et al., 1980). 
2.3. Catcuta~~ons 
The microsphere and other data were processed by a PDP-11/70 computer 
using a set of specially deveJ.oped programmes (Saxena et al., 1980) 
Tissue blood fl.ow (O __ ) was calculated by: 
"t>S 
where Iart and Qart represent arterial blood radioactivity 
and withdrawal rate (ml.m.in -~), respectively, and I tis 
radioactivity (c.p.m.) in a particular tissue sample (Johnston and 
Saxena, 1978). ~1 blood flow values were normalized for lOO g tissue 
weight. 
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2.4. Sxper~men~a~ pro~coL 
The first batch of microspheres was injected about 1.5 m:in after the 
completion of the surgery to measure the tissue bl.ood flow at the 
baseline. Five minutes later each rat was injected with either 1.0 J.L9 
of OSTLE ( dissol.ved in 2 J.Ll. artifical CSF) or the same vol.~ of the 
vehicle into the left 1ateral ventz::icle. The rats were then divided 
into 6 groups ( n=6 each) and a second batch of mi.crospheres was given 
after either 2.5, 5 or 10 minutes following administration of DSTLE or 
CSP. 
JUst before the injection of microspheres, values of heart rate and 
arterial blood pressure were collected and arterial blood was 
withdrawn for the determination of blood gases. 
2.5. NeuronaL ~~v~~y 
In order to confirm the seizure activity of DSTLE, five rats belonging 
to the "1.0 min" series (see above) had been implanted at least 7 days 
before the actual. experiment with suitable el.ectrodes to record ECoG, 
hippocampal EEG and the electrical activity of the submandibular 
muscles (Chapter VI). 
2.6. Da~a presen~a~~on and s~at~s~tcat evatua~~n. 
Al.l data have been expressed as mean ± s. E. of the mean. The values 
Obtained at different time intervals after CSF administration have 
been placed together in the Tables. However, statistical compariSon 
was always made between the values obtained at 2. 5, 5 or l.O min after 
DSTLE administration and those obtained at the corresponding time 
intervals after injection of CSP, thus eliminating the influence of 
the microsphere injection. The changes in the haemodynamic variables 
from the baseline values were cal.culated in each experiment and the 
significance of these changes was determined by using the Wilcoxon 
matched-paired signed-rank test (Si.egel, 1.956 ). FUrthermore, since 
corresponding experiments with CSP were conducted, the changes 
obtained 
compared 
at different time intervals after DSTLE administration were 
to those after 
Mann-Whitney u test (Siegel, 
CSP 
1956). 
adm::ini.straion using 
statistical significance 
accepted at p-values of 0. 05 or less (two-tailed) . 
the 
was 
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Tabl..e 1 • Bl.ood gases ana ha~modynamtc vari-ab<&es. 
Mean vaz.u.es ± SEM of "the heart rat.e (E!R), mean arter-tal.. b:z..ood pressure 
(MBP) and ~ertal.. bl.ood gases tn rats before (baseZ.tne) and 2.5, 5 or 
10 ~n ajt.er tnt.racerebrovent.r~Lar (tvt.) tnj~~n of 8 rece~r 
pept.tde (DSTLE, 10 ~g) or arttjtcal.. cerebrosptnaL fLuta (CSF, 2 ~L). 
min after DSTLE 10 !.LQ. ivt 
CSP 2.5 5 10 
pH 7.29 7.27 7.29 7.26 
43±2 4].±1 41.±1 41±3 
1.17±43 1.15±2 109±3 1.17±5 
l'C02 (Bg Dll) 
P02 (Bg mm) 
so (%) 
7.27 
43±2 
1.12±3 
96±0.6 97±0.6 97~.2 96±0.4 97±0.-1: 
2 
HR (beats/min) 
MBP (!lg lliDl) 
347±7 
1.02±3 
s 0 , 'haemoglobin saturation 2 
340±20 
1.07±9 
31.7±24 330±19 333±21 
S7:t9~ 75±71r 83±9* 
* change was significantly different when compared with the 
corresponding change in control ( CSF) ani.mal.s as we11 as 
from baseline values. 
3. RESULTS 
3 .1.. BZ.OOa gases 
No changes were noticed in the arterial blood gases at different t~ 
intervals after CSF or DSTLE (Table 1 ) • 
3.2. B~d pressure and hear~ ra~e. 
Baseline values of the arterial blood pressure and heart rate and the 
changes produced by DSTLE or CSF are given in Table 1. When compared 
with CSF, the DSTLE injection caused a significant decrease in tnean 
arterial blood pressure, while there was only a slight initial 
decrease in the heart rate ( statistically not signifi.cant) . Compared 
to the baseline values, no differences of these haemodynamdc variables 
occured after CSP administration. 
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E£fect of intraventricular injection of CSF or DSTLE 
As shown in Table 2, the distribution of the blood fl.ow to the 
different brain structures was little affected by ivt administration 
of CSF ( 2 p.l) • However, the administration of DSTLE was associated 
with a significant increase of the blood flow to both left and right 
hippocampus within 2.5 min after the drug injection. This effect, 
which was more marked at the side (left) of drug admi.ni.stration, 
reached its peak at s min and was still noticeable 10 min after DSTLE 
injection. At the time of peak effect in the hippocampus, blood flow 
also increased in the striatum, cerebellum and brain stem. 
cerebral cortical blood flow was not significantly modified but, s min 
after injection, it was more in the drug-treated animals than in the 
animals given CSF. No changes were noticed in the l.ateral septum, 
hypothalamus and thal.amus. 
!~a!ev!~u::g:a~ ~~~ef!~~d fLo~ (mL.mtn-1.100 g- 1) ~o var~us 
bratn reg~ns tn ~he ra~~ Detore (base~~ne) and 2.5~ 5 or 10 m~n at~er 
~n~racerebroven~r~cu~ar (~v~) aam~n~s~ra~ton Of S recep~r pep~~e 
(DSTLB~ 10 ~g) or ar~~ttca~ cerebrosp~na~ t~u~d (CSF, 2 ~~). 
No~ ~he s~gn~ttcan~ ~ncrease ot ~he f~OQ ~ ~he s~r~a~um~ h~ppocampus 
cerebe~~um and bra~n s~em (p<0.05, n--6 tor each ~£me per~). 
m:i.n after DSTLE, 10 ~. ivt 
Regions baseline CSP 2.5 5 10 
left cerebral cortex 50±2 48±3 47±3 55±2""* 49±.5 
right cerebral cortex -46±4 48±7 41.±6 49±6 49±4 
left striatum 49±3 4:5±3 43±4 61.±2"" 47i:6 
right striatum 44±4 40±4 38±6 53±3"" -46±4 
lateral sePtum 25±3 28±2 24±5 29i:3 26±2 
+ hypothalamus 
left hippocampus 40±4 -46±2 77±9"" 1.31.±28"" 61.±9"" 
right hippocampus 33±4 31.±1. 4:9±6* 75±14* 46±6"" 
left thalamus 60±8 65±7 59±9 63±2 55±5 
right thalamus 51.±6 60±8 54':1:4 61±9 56±9 
cerebellum 65±4 53±7 65±5 93±1.3* 63±2 
brai.n stem 59±1. 54±4 71.±5* 78±9* 5Si:7 
total. brai.n 51%4 47±4 51.±5 67±4"" 55±5 
* ~change was significantly different when compared wi.th the 
corresponding change in control ( CSF ) animals as well as from 
baseline values. 
""*,significantly different only from control ( CSF) values. 
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DSTLE.IVT 
CONTROl !2.5" 
10. 
EMG~III"''-1""1 'i'!l;illoMIQI!li >illtllilll 11!1\\n~~~~~ ~~+~~~4~ 
II I_ 
5 SEC !100 fV 
~g.l. E~ec~romyogram (EMG of ~he submandi-buLar muscLes), 
eZ.ec'trocorti.cogram (ECoG) and hippocampaL EEG (Hf,p), before and af-ter 
tnt;raven"trtcutar (tvt) aamtnts'trat~n ot s recep-tor pep-ttae (DSTLE 10 ~g) 
t.n ra-t. 
3.3. Regtonat cerebraL bLood fLo~. 
Baseline values 
Basel~ne values of the distribution of the carotid artery blood flow 
to the various brain structures are given in Table 2. Amongst the 
different regions of the brain, the blood flow to the cerebellum was 
the highest and that to the lateral septum and hypothalamus, the 
lowest. FUrthermore, the left side of the brain areas received 
slightly, but consistently, higher blood flows than the corresonding 
areas of the right side. Th:i.s var:iation may be due to mechanical 
irritation caused by the introduction of the cannula into the left 
lateral ventricle. 
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3.4. Effec~ Of DSTLE on neuronaL act~v~ty 
Figure 1 shows the records from one of the five an~ls (10 min 
series) where neuronal. activity was recorded. As has been reported 
earl.i.er (Chapter VI), ivt administration of DSTLE increased the 
submandibular muscle activity ( EMG) and caused epileptic discharges in 
the ECoG and hippocampal EEG. The effect was noticeable within 2.5 
min and reached its peak spike activity at about 5 min. Though still. 
noticeable, the above effects were reduced after l.O mi.n. 
hippocampal blood flow in this animal was 42 and 55 ml.min - 1 .1.00 
The 
-~ g 
respectively at the baseline and 1.0 min after the administration of 
DSTLE. 
4. DISCUSSION. 
The administration of DSTLE significantly decreased the mean arterial blood 
pressure. This is in accordance with previous findings ( Bolme et 
al., 1978) demonstrating a similar reduction of the arterial pressure after 
2 5 
the administration of another putative B op~ate agonist, (D-ala , D-leu ) 
enkephal.in. Though the phys~ologicaJ. role of the s opiate receptors in the 
control of blood pressure is not well understood, it may be noted that ICI 
154 129, a selective s opiate antagonist (Shaw et al., 1982), can cause a 
transient increase in arterial blood pressure (Clark and Reid, 1984) . 
Regional cerebral blood flow was not substantially altered ~ the 
administration of CSF but the increase of the flow to the different brain 
areas after DSTLE injection was clearly demonstrated and was more 
pronounced at the side where the drug was injected. The enhancement of 
cerebral blood flow after the administration of the 5 opiate agonist 
occured Wi.thin 2. 5 min and reached its peak at about 5 :min after the 
injection. This time course corresponds with that of the EEG epileptic 
spiking (Figure l) and the increased deoxyglucose uptake (Chapter VII) 
after i vt administration of DSTLE. Amongst the brain regions, the blood 
flow to the hippocampus increased most intensively and for the longest 
period. This is in accordance with our earlier observations that ivt 
administered enkephalin reaches the hippocampus within 2.5 min (Chapter V),: 
has the shortest onset of epileptiform discharges and a long lasting EEG 
- 104 -
spike activity (Chapter V). FU.rthennore, the 2-deoxyglucose uptake, as a 
parameter for energy metabolism (Sokoloff, 1977 ), was significantly 
increased in the hippocampus after endorphin admi.nistration (Henriksen et 
al., 1982), specifical.ly in the subicular/CAl. region (Chapter VII). The 
most intensive and long-lasting increase of the hippocampal blood flow 
after enkephaJ.in appl.ication, as observed in thi.s study, which apparently 
reflects an increase of the neuronal activity, suggests that this brain 
region pLays an essentLal role in the opioid peptide-induced seizure 
phenomena. 
The increase of the blood flow to the striatum 5 min after the erikephalin 
injection might be due to its periventricular position and the presence of 
0 opiate receptors {Duka et aL, 1961). Furthermore, it is known that 
parts of the striatum are activated following electrical stimulation of the 
hippocampal. formation (watson et al., 1983). The brain stem a.J...so shows and 
increased bl.ood flow after DSTLE adm.i.nistration. This brai.n area is rich 
of opiate receptors ( Atweh and Kuhar, 1977) and the enkephal.ins are quickly 
distributed in the l.iquor space after an ivt injection (Chapter V), 
although an excitatory input to this area can not be excluded. 
An increase of the blood flow to the rat cerebellum after erikephal.in 
administration is an unexpected phenomenon, since this region has a very 
l.ow density of opiate receptors (Atweh and Kuhar, 1977) and only the 
per:ikaJ::ya of the Golgi cel.ls stain positively for enkephal.in (sar et 
al.., 1978). A possible excitatory input via the mossy- and climbing 
fibers, originating from the perikarya located in the brain stem and spinal 
cord, to the cerebellum, might be a reason for the increased neuronal 
cerebelLar activity associated with a rise in blood flow to this region. 
unfortunately, the cerebell.um was not included in our previous experiments 
where we studied the 2-deoxyglucose uptake during enkephalin-induced 
epilepsy (Chapter VII). 'l'his precl.udes a comparison between the observed 
flow increase after DSTLE administration and the possible rise of the 
metabolic rate in the cerebell.um. Evidentl.y, additional experiments are 
needed to elucidate the role of the enkephal.ins in the cerebel.lum, 
particularly in the light of various cl.inical. evidences suggesting a strong 
rel.ationship between the cerebell.um and some types of epil.epsy ( coopex, 
1973; WOOd et al., 1977). 
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Lastl.y, though we demonstrated a strong rel.ati.onship between the 
electrophysiological. recordings and energy metabolism in the cortical. 
region (Chapter VII ) , in this study we did not observe a marked increase in 
blood flow to this region after admi.n:istration of OSTLE. This di.screpancy 
may be due to the nature of cortical tissues examined in the two studies. 
While we i.sol.ated the cortical areas for the measurements of deoxyglucose 
uptake (Chapter VII), the relatively poorer reso1ution of the radioactive 
m.icrosphere technique for blood flow determi.nation ( saxena et aJ.., 1.980), 
required us to exami.ne large cortical areas which included a substanti.al. 
amount of white matter. It is therefore quite l.ikely that an increase in 
blood flow to the cortical nuclei may have been masked by the "over-all" 
cortical blood flow measured by us. 
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SUMMARY AND CONCLUD !NG REMARKS 
Part l.. 
Before the major d:iscoveries in the past decade, opiates were known to 
possess selective and unique pharmacological properties. To elucidate 
their role in relation to excitatory phenomena which they might induce, it 
i.S i.mportant to have a better understanding of the ph.ax:macologi.cal and 
pharmacokinetic properties and the distribution of the opioids. Chapter l. 
reviews the chemical relationships, biogenesis and degradatl.on of the 
opi.oid peptides ( enkephalins, endorphins and dynorphi.ns). Of particu1ar 
interest are the enzymes which are involved in their inactivation, since 
inhi.bi.tors of these enzymes can be considered as useful tools in 
pharmacological research. Enkephal:i.n-li.ke peptides are found at every 
level of the neuraxis, including cel.ls in the cortex all the way to cells 
in the spinal cord. 13-endorphin/ACTB related peptides are found in the 
medial baSal hypothalamus and projects its fibers very widely, including 
many areas of the limbic system and brain stem. DynorphinS are found in 
the posterior pituitary and several other brain regions. These three 
opioid neural pathways are described in more detail in Chapter 1.. 
Opioid peptides exert their effects through binding with opiate 
receptors (Chapter II). This binding is stereospecific~ saturabl.e and 
reversible. The question arises Whether or not the different opioid 
peptides interact with one and the same receptor or whether there are 
several receptors sul>servi.ng different physiological functions. This i.s of 
particular importance since the synthesis of highly specific ligands for 
one receptor class would then become possible and could provide drugs of 
clinical importance such as analgesics ~th low addiction potential. 
Indeed, different opLate receptor sUbtypes have been found of which the 
most important ones: A receptor that prefers morphine 1 Which was cal.led 
the JJ. receptor; A receptor that prefers enkephal.ins 1 called the s opiate 
receptor and a dynorphin binding site, which was ca.J.led the K receptor. 
Many opiate drugs interact at multiple receptor sites. However, some 
peripheral and pharmacological effects have been ascribed to the different 
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opiate receptor subtypes. Por examp1e, interactions with ~ receptors 
produce ana.J.ges:ia, bradycardia and hypothermia, whereas s receptors can be 
bel.d responsil:>le for convulsive, sedative and behavioural effects (Chapter 
III). 
Recent studies have demonstrated an ~rtant rol.e for endogenous 
opioid peptides in the limbic system parti.cularl.y in the hippocampus 
(Chapter IV). Although the predominant action of opioids in the nervous 
system is a naloxone-reversible depression, they excite hippocampal 
pyramidal cel.l.S, which may underl.i.e epileptic episodes induced by 
enkepha.li.ns. Three major hypotheses have been proposed to explain these 
excitatory phenomena in the hippocampus: 1. Excitation by disi.nhibi.tion; 
2. Pacil.i.tation; 3. Increased efficiency of coupli.ng. A bulk of 
evidence favours disinhibition as responsible for excitatl.on of hippocampal 
pyramidal cells by opioid peptides. 
Part Z. 
Most neuropeptides are known to occur both in the central nervous system 
and in blood, and although central effects occur after peripheral 
administration of the peptides, the reLationship between these two 
compartments haS hard.J.y been studied. For many peptides, such as the 
enkephalins, poor penetration into the brain via the blood brain barrier 
has been demonstrated by Heisenberg and si:mmons ( 1983). The diffusion of 
the most peptides across the brain vascular endothelium seems to be 
severely restricted and forms the main obstacle for the development of 
peptides, as useful therapeuti.c agents. 
A second problem which £aces opioid peptide research is the 
bi.otransformation of these sUbstances in the cerebrospinal liquor space. 
In this respect, the presence of erikephalin degrading enzymes in the 
cerebrospinal fluid ( CSF) is of particular importance. These factors, 
together with the high costs of the compounds, urged investigators in 
opioid research to use the intracerebroventricuJ.ar ( icv) route of 
administration. However, many aspects which affect ivt adml.nistration of 
enkephalins such as the distribution, elimination and biotransformation of 
these sUbstances, were not clear and made interpretation of the results 
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rather d~fficult. 
By usi.ng a physiologically stable enkepha.l.:i.n analogue, like (D-a1a2 , 
D-leu 5 ) enkepha.U.n ( OADL), at least one of the problems was circumvented 
(Chapter V). Tritium labelled DADL reached all parts of the ventricuJ.ar 
system, including the central canal of the spinal cord and the 
extracerebral ventricular space, within 10 min after icv administration. 
However, electrographic epileptic phenomena occured within 1.-2 mi.n after 
the application which suggests the presence of an opioid proconvulsant 
system in the vicinity of the Lateral ventricles. The bra.i.n regions 
bordering the lateral ventricles are the striatum, septum and hippocampus, 
in whi.ch penetration of the labelled enkephalin occured upto a depth of 
about 100 ~ during the first 2 min. Compar:ison of the 
electrophysiological responses of these three regions after icv enkephalin, 
made us suggest that the hippocampus plays an essential role in the 
opioid-induced seizures. In this region sp~e activity was very intense 
and long-lasting and it is known that the hippocampus has a low seizure 
threshold (cowan et al., 1979). 
since we used DADL, which haS a J.ow discrimination ratio between s and 
JJ.. opi.ate receptors (KosterJ.itz and Paterson, 1981), the characteristics of 
the convulsant system i.nvoJ.ved remai.ned unresolved. It is suggested that 
the analgesic action of opiates is mediated by JJ.. opiate receptors (orca et 
al., 1977; ChailJ.et et al., 1984) while the excitatory phenomena induced 
by opioid peptides emerge from s opiate receptor stimulation (Dzoljic and 
vd Poe1-Heisterkamp, 1.982), although Gahw:iler demonstrated JJ.. receptor 
involvement in these phenomena ( 1981). To elucidate the role of these two 
opioid systems in the opiate-induced epileptiform seizures, the highly 
specific s opiate agonist, o-tyr--ser-gly-phe-leu-thr (DSTLE) {Gacel et al., 
1980) and morphiceptin, which shows a high specificity for the IL opiate 
receptors (Chang et al., 1981; Zhang et al., 1981; Chang et al.., 1982) 
were used (Chapter VI). Indeed, icv DSTLE caused a dose-related increase 
of the myoclonic contractions ( MC) of the submandil:>ul.ar muscles. 'l'he use 
of the number of MC, as a parameter for epileptiform activity, :is justified 
by the fact that they are correlated with the ECoG and EEG epileptic 
spikes. Morphiceptin had no significant effect on the EMG or ECoG but, 
interestingly, inhibited the DSTLE-induced seizures in a dose-related 
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manner. These results support the terms ··proconvulsant 5 opiate receptors" 
and ••anticonvulsant Jl. opiate receptors" as proposed by Dzoljic ( 1.982) and 
Frenk ( 1983). FUrthermore, the DSTLE-induced MC were inhil>ited by low 
doses of the specific 5 opiate antagonist, ICI 1.74,864. 
The convulsions induced by electroshock or kindling are probably mediated 
by increased endogenous levels of endorphins and enkephal.ins (Hong et 
al., 1979; Vindrola et al., 1981). The recently described antagonism of 
exogenously applied opioids.. on these seizures (Berman and Adler, 1984; 
Puglisi -Allegra et al. , 1984) may depend on the route of administrati.on 
(Prenk, 1.983) or, as stated above, upon stimuLation of the different opiate 
receptor subtypes. In this case it should be interesting to examine the 
effects of enkephal.inase inhibitors, which potentiate the endogenous 
enkephalinergic system, on these convulsant 
induce epileptic phenomena when injected 
1.984). Whether endogenous (leu )enkephalin, 
manipulatl.ons, while they 
alone ( Ukponmwan and Dzol j i.e, 
the putative S agonist, is 
involved remains to be established. 
Increased levels of endorphins are observed during anaesthesia (Berkowitz 
et al., 1.976). This might explain the increased electrographic excitation 
dur~g anaesthesia, as well as the facilitatory effect of urethane on the 
DSTLE-induced epileptiform phenomena. Apparently, the effects of opioid 
peptides can be significantly modulated by the J.evel of anaesthesia. other 
data indicate that the effects of morphine, which acts on the same opioid 
peptidergic system, can either be inhibited or facilitated by urethane 
anaesthesia (orca and Liebeskind, 1.979; Linseman, 1.980). This indicates 
the necessity of parallel studies with opioids in free-moving animals. 
FUrthermore, these findings might be of clinical importance, specifically 
in the treatment of post-operative pain. 
DSTLE injected icv in free-moving an~ls resulted in severe wet dog shakes 
and "falling downn. These wet dog shakes were associated with a very 
intense electrographic epileptic spike activity. Wet dog shakes can also 
be observed during naloxone-precipitated withdrawal in morphine 
tolerant/dependent rats and mice, and are associated with a considerable 
increase in the plasma endorphin immunoreactivity. These findi.ngs may 
reflect the stress associated effects in these experiments, since stressors 
are potent stimuli to endorphin release (Guillem.i.n et al., 1977). Much 
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like the shivering and "chills" which accompany withdrawal. symptoms in 
humans, it seems poss~le that the thermogenic effects of wet dog shakes 
with an assoc:iated heat conserv:ing behaviour, could represent an anlogous 
situation in rats. These behavioral epileptic phenomena (MC and wet dog 
shakes) are probabl.y the result of act:i.vation of the l.i.mbic system, which 
:is known to control. motor behavior. 
Increased neuronal activity, as observed during DSTLE-induoed epileptic 
phenomena, should be correlated with an increased energy metabolism and as 
such wi.th a rise of the blood fl.ow to the regions i.nvol.ved in these 
phenomena. By using the "punching" techn:i.que we were able to isolate the 
different brai.n nuclei, while Sokoloff's (1.977) 2-deoxyglucose technique 
was used to determi.ne the energy metabol.ism :ln these regions during 
enkephalin-i.nduced neuronal activity (Chapter VII). Generally, the l.i:mbic 
system showed a higher glucose uptake compared to the other brain areas, 
which corresponded with the more intensive and longer-lasting sp~e 
activity, as recorded after icv DSTLE. Since our attention was focused on 
the hippocampal area, we isolated the different structures/nuclei of this 
region. Compared to the Cl\2., CA3 and dentate gyrus, the CAl and subiculum 
showed a significant increase of the energy metabolism during epileptic 
phenomena. 'l'he onset period of the CAl sp~e activity after DSTLE 
administration was very short (within 1 tni.n), which suggests an opioid 
mediated excitatory mechanism/pathway in the close vicinity of the lateral. 
ventricle, where indeed the pyramidal cells of the CAl. are located. In 
this short period of time, the enkephalin penetrated to a depth of about 
50-100 J.Ull. Activati.on by opiates of the pyramidal cells might, via 
i.nterneurons, result in a decreased release of GABA, which may lead to 
excitation ( Zi.eglgansberger et al., 1979). Indeed, G2\BA antagonists 
potenti.ate the opiate-induced epileptic activity (Dzoljic et al., ~978) 
whi.le Gru3A inhibits these phenomena (Illes, 1982). 
Similar conclusions can be drawn from the measurements of the blood 
flow to the different regions after administration of the enkephal.in 
analogue (Chapter VIII). The increase of the blood flow to the striatum 
and brain stem after the application of OSTLE, might be a result of the 
high densities of opiate receptors in those regions ( Duka et al., 1981). 
However, an excitatory input, probably originating in the limbic system, 
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can not be excluded. 
An unexpected findi.ng was that the opi.oi.d peptide aJ.so enhanced cerebellar 
blood flow. It is known that this region has a very low density of opiate 
receptors ( Atweh and KUhar, 1977) i only the perikarya of the Golgi cells 
stain positively for enk.ephali.n (Sar et al., 1978) and its location is far 
from the lateral ventricl.es. Thus, it is not likely that the compound can 
easily reach these structures during the first minutes, when the blood flow 
increase occurs. Although, if so, a similar mechanism as is proposed for 
the op:iate-i.nduced hippocampal excitations disi.nhi.bition 
(Zieglgansberger et al.., 1979), might occur :in the cerebellum as well, 
since this br~n region has a relatively high concentration of GABA-ergi.c 
neuronesjpathways (CUrtis et al., 1.970). However, an excitatory input via 
the mossy- and climbing fibers, originating from the per~ in the brain 
stem and spinal GO:td, to the cerellellum, might be an additional reason for 
the increased neuronal cerebell.ar activity associated with the rise of the 
blood flow to this region. The results suggest the necessity of further 
experiments concerning the relationship between the enkephalins and the 
cerebellum, particularly because clinical evidence suggests a strong 
relationship between the cerebellum and some types of epilepsy, which are 
associated with a decrease of the CSP GABA levels (Cooper, 1973; Wood et 
aL, 1977). 
Noteworthy is the strong correlation between the EEG recordings, which 
reflect the neuronal activities, the energy metabolism and the blood flow 
of the different areas. 
In summary, the results presented in this dissertation, permit the 
following general conclusions: 
l. EnkephaL~ns, aam~n~s~erea ~cv, reach aLL parts of the ventrtcuLar system 
~ncLud~ng the centraL canaL of the sptnaL cord and the e~racerebraL 
spaces ~th~n 10 mtn. 
2. The sUbstance penetra'tes ~n'tO the pert:.ventri.cu.Lar ttssue to a aepth of 
about 100 pm ut:.thtn 2.5 mt:.n. 
3. Acttvat~n of S opt:.ate receptors t:.s essent~aL for the tr~gger~ng of 
optot:.a-tnauced ept:.Lept~form phenomena, ~ht:.Le acttvat~n of ~ optate 
receptors has a more anttconvuLstve effect. 
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4. T?'le snort onset Of ac-etvt:ty a;t"ter 
entcephaZ.t.ns, sugges-ts 
convuLsant; sys"tem t.n "the vtct.nt"ty of "the La"teraZ. ven"trtcz.es. 
5. Thts convuLsant system t.s probabLy z.ocatea tn the htppocampus, tn ~htch 
the CAl or subtcuz.ar area can be heLd responstbZ.e :tor the trtggertng 
From tht.s area, 
ezctta~ry pa"th~ays may run ~ other bratn regtons, Z."Lke the brat.n stem 
ana cerebeLLum. 
6. In the cerebeLLum, the enkephaZ.t.ns may pLay an tmportant rote tn some 
types of eptZ.epsy. 
7. No~uorthy ts the strong corretat~n be"tueen the neuronaL acttvtt;y, 
energy metaboZ.tsm and bLood fZ.ou t.n the dtfjeren"t brat.n regtons. 
It shouJ.d be emphaSized that the pharmacological. effects ( epil.ept:ic 
d:ischarges and excitatory behaviour) of the opi.oi.d pepti.des 1 as described 
above, have been demonstrated with exogenous administration of opioi..ds. 
However, the spike activity and excitatory behaviour can also be observed 
after administration of enkephalinase inhibitors (Ukponmwan and Dzoljic, 
1984), which indicates that endogenous opioid peptides may have simi~ar 
actions. consequently, the endorphins/enkephal.ins seem to be important 
physiological. modulators of neuronal excitability in the CNS. 
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SAMENVATTING 
Deel. l.. 
Boewel opiaten reeds eeuwen toegepast worden op grond van hun unieke 
ei.genschappen, is pas in de laatste jaren een basis gelegd voor enig 
begrip omtrent hun werking. Om een inzicht te verkrijgen in de rol van 
de opioid peptiden met betrekking tot de excitatie verschijnselen, 
welke zij kunnen induceren na een systemische of intraventriculaire 
toediening, is bet belangrijk eerst meer te weten over de eigenschappen 
en de verspreidi.ng van deze stoffen en de mechani.smen, waa.rin ze 
betrokken z:ijn. 
Boodfsttik I geeft een overzicht van de chemische structuren, de 
biosyntbese en de afbraak van de opioid peptiden ( enkefalinen, 
endorfinen en dynorfinen). Belangrijk hierbij zijn de enzymen, die 
betrokken zijn bij de inactivatie van de opioid peptiden, omdat remmers 
van deze enzymen als belangrijk hulpmateriaal kunnen beschouwd worden 
bij farmacologisch onderzoek. Erikefalinen worden overal in het 
centrale zenuwstelsel gevonden, van hersenschors tot ruggemerg. 
Endorfinen worden aangetroffen in de mediale basale hypothalamus, waar 
vanuit zenuwbanen naar het limbische systeem en de hersenstam lopen. 
Dynorfinen worden gevonden in de neurohypofyse en in verschillende 
andere hersengebieden. Deze drie door opioiden gemedieerde neuronale 
systemen worden meer gedetai.ll.eerd beschreven in Hoofdstuk I. 
De werking van opioid peptiden komt tot stand door binding aan 
speci£ieke opiaa.t receptoren ( Hoofdstuk II). opi.aat receptorkinetiek. 
wordt gekarakteriseerd door stereospecificiteit, verzadigbaarheid en 
omkeerbaarheid. Aangezien er verschillende opioid peptiden bestaan, 
rijst de vraag of deze aan dezelfde receptor binden of dat er voor de 
verschillende fysiologische eigenschappen odk verschillende receptoren 
bestaan. Indien dit Laatste bet geval is, zou het van kl.inisch belang 
kunnen zijn omdat dan de mogelijkheid ontstaat om receptor-specifiek.e 
geneesmiddelen te ontwikkelen zoals analgetica zonder verslavende 
eigenschappen. 
TOt op heden zijn er inderdaad verschillende opiaat receptoren 
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gevonden, met name, de p. opiaat receptoren, welk.e bij voorkeur morfine 
bi.nden, de 8 receptoren met een voorkeur voor enkefalinen, de K- of 
dynorfine-receptoren en de ~ en E receptoren, hetgeen echter ~et 
uitsluit dat de verschillende opiaatachtige stoffen aan meerdere 
receptoren kunnen binden. 
Wel worden verschillende effecten van opiaten toegeschreven aan een 
activatie van specifieke receptoren. .Analgesie, bradycardie, en 
hypothermie komen bijvoorbeeld tot stand via activatie van de JJ. 
receptoren terwijl 5 receptoren verantwoordelijk zouden zijn voor 
convul.si.es, sedat:ie en veranderingen in gedrag (Hoodfstuk III). 
Recente studies hebben aangetoond dat endogene opioiden een 
beLangrijke rol spelen in bet limbische systeem, voornamelijk in de 
hippocampus (Boodfstuk IV). In tegenstelli.ng tot de werking van 
opioiden in de rest van bet centrale zenuwstelsel, waar zij de 
act1viteit van neuronen remmen, leidt toediening van enkefalinen in de 
hippocampus tot een verhoogde activiteit van de hi.ppocampale pyramidale 
cel.len. Dit zou een onderli.ggend mechani.sme kunnen zijn van de 
epileptogene werking van enkefalinen. 
bestaan drie mogelijke verklaringen: ~. 
dl.sinhibi.tie; 2. Pacilitati.e; 3. 
impulsoverdracht. 
Voor deze exci.terende werking 
Excitatie als gevolg van 
Verhoogde effi.ci.entie van de 
Op grond van resultaten van meerdere onderzoeken, 
hypothese de meest waarschi.jnlijke te noemen. 
Deel 2. 
is de eerste 
Terw'i.jl de meeste neuropeptiden zowel in het centrale zenuwstelsel al.S 
in het bloed voorkomen en hoewel effecten op het centrale zenuwstelsel 
onstaan na i.ntraveneuse toediening van opioi.d peptiden, is een relatie 
tussen deze twee compartitnenten nauwelijks bestudeerd. Heisenberg en 
Simmons ( 1983) hebben aangetoond dat veel peptiden, b. v. enkefal.inen, 
de bloed-hersen barriere slecht kunnen passeren. Diffusie van de 
meeste peptiden door bet endotbeel van bloedvaten in de hersenen lijkt 
nauwelijks plaats te vinden, hetgeen een groot obstakel is voor de 
ontwikkeling van therapeutisch toepasbare peptiden. Biotransformatie 
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van opioiden in de liquor cerebrospinalis door daar voorkomende 
enzymen, iS een tweede prob1ee~ waarmee onderzoekers op het gebied van 
peptiden, worden geconfronteerd. Mede gedwongen door de hoge kosten 
verbonden aan het gebruik van opioiden, noopten deze factoren 
onderzoekers tot het gebru~en van de intraventriculaire manier van 
toedienen. Echter, veel aspecten die van invloed zijn op de 
intraventriculaire toediening ( ivt) van enkefalinen, zoals 
verspreiding, el~natie en biotransformatie, waxen oribekend en maakten 
de interpretatie van resultaten moeilijk. 
Door gebruik te maken van een stabiel enkefal.i.ne, zoals 
2 1 5 -(D-a1a ,D- eu ) enkefall.ne (DADL), kon tenminste een van deze problemen 
omzeild worden (.Hoofdstuk V). In een studie, waarbij gebruik werd 
gemaakt van tritium-gelabeld DAOL, bleek deze stof binnen 10 min na ivt 
toediening, alle delen van het ventricuLair systeem waaronder het 
centraal kanaal en de extracerebraleruimte bereik.t te hebben. Echter 
tijdens de eertse 2.5 minuten, na toediening, verschijnen epileptische 
pieken i.n het EEG. oeze tijdsperiode komt overeen met penetratie van 
het enkefaline in de periventricul.aire weefsels (hippocampus, striatum, 
septum) tot op een diepte van l.OO ,um. Di.t wi.l zeggen dat er een opiaat 
receptor-gemedieerd epileptogeen systeem in de onmidddeli.jke nabijheid 
van het laterale v0.ntrikel moet liggen. EEG'S van de verschi.llende 
hersengebieden tonen aan dat na een ivt toediening van erikefaline, de 
eerste epileptische ontladingen ontstaan in de hippocampus. 
Omdat we in ons onderzoek gebru~ maakten van het niet-specifieke 
DADL bleven verdere karakteristieken van bet convulsie£ systeem 
onopgelost. Echter, ivt toediening van de speci.fieke J.L en 5 opiaat 
agonisten, respecti.velijk morphicepti.n en 5 receptor peptide ( DSTLE), 
toonden aan dat deze excitatie- en epileptische verschijnselen het 
gevolg zijn van een activatie van de 5 opiaat receptoren, terwijl 
activatie van J.L receptoren resulteerde in een anticonvusie£ effect 
( Hoofdstuk VI ) • Voorafgaande toedieni.ng van zeer lage doses van de 
specifi.eke 5 antagonist, ICI 174;864, blokkeerde de DSTLE-geinduceerde 
epileptische ontladingen. Deze resultaten ondersteunen de termen 
"proconvuls:ieve 5 receptoren" en "anticonvulsieve J.L opiaat receptoren". 
Oit deze experimenten bleek ook dat narcose een stimulerende invloed 
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uitoefende op de DSTLE-geinduceerde excitaties. Een verklar1.ng 
hiervoor moet waarschijnlijk gezocht worden in een verhoging van de 
endogene opioid concentratie, tijdens narcose. Hieruit blijkt de 
noodzaak voor gelijklopende onderzoeken in wakkere dieren. Bovendien, 
zouden deze bevindingen van klinisch belang kunnen zijn vooral in 
verband met het behandelen van post-operatieve pijn. 
DSTLE, ivt toegediend in vrij-lopende ratten, resulteerde in ernstige 
"Wet dog shakes". Deze "Wet dog shakes·· zijn geassoci.eerd met intense 
piek activiteit in het EEG. Gel.ijkaardige "Wet dog shakes·· kunnen ook 
ontstaan tijdens de onthoudingverschijnselen in morfine versLaafde 
dieren en zijn bier geassocieerd met een aanzienlijke toename van de 
pLasma erikefaline concentratie. oeze resultaten zouden een 
weerspiegeling kunnen zijn van stress factoren tijdens de experimenten, 
omdat stressors sterke stimuli zijn van endorfine afgifte. Net zoals 
het rillen bij mensen tijdens het onthoudingssyndroom, zouden ~ dog 
shakes·· een ana.J..oge si.tuati.e kunnen zi.jn bij ratten. oeze epilept:ische 
verschi.jnselen in bet gedrag zi.jn waarschi.jnli.jk bet resultaat van een 
acti.vatie van het limbische systeem, dat een controlerende invloed 
ui.toefent op de motori.ek. 
verhoogde neuronale activi.tei.t, 
logischerwijs gepaard moeten gaan 
gei.nduceerd 
met een 
door DSTLE, 
verhoging van 
zou 
het 
energieverbruik in de betrokk.en hersen gebi.eden en als zodanig met een 
toename van de bloeddoorstrom:i.ng. S:et toepassen van de "punching" 
techniek stelde ons in staat verschi.llende hersen nuclei te 
terwijl Sokoloff's 2-deoxygluoose techniek werd gebruikt 
isoleren, 
om bet 
energieverbruik in deze gebieden, tijdens DSTLE-geinduceerde epilepsie, 
te meten ( Hoofdstuk VII). over bet algemeen, vertoonde het limbisch 
systeem een hogere glucose opname in vergelijking met andere hersen 
gebieden, wat overeen komt met de sterkere en langer durende piek 
activiteit in bet EEG. vooral. bet CAl. gebied van de bipppocampus en 
bet subiculum vertoonden een sterke toename van de gl.ucose opname. De 
J.atentietijd van DSTLE--geinduceerde pieken was erg kort ( < 1 mi.n) in 
bet EEG van bet CAl./subiculum. Oit suggereert een opioid gemedieerd 
convul.sief systeem in de onmiddelijke nabijheid van het laterale 
ventrikel, waar inderdaad de pyramidale cel.len van het CAl. gelegen 
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zijn. Activatie door opioid pepti.den van de pyramidale cel.l.en kan, via 
interneuronen, resul.teren in een verminderde GABA afgifte, wat op zijn 
beurt kan leiden tot een excitatie. GABA antagonisten potentieren deze 
enkefaline-geinduceerde excitatieverschijnselen, terwijl GABA zelf deze 
actvatie remt. 
Gel.i.jkaardige conclusies kunnen worden getrokken uit de 
de verschillende experimenten waa:r:bij de doorbloed:ing van 
hersengebieden, tijdens DSTLE-geinduceerde epil.epti.sche fenomenen, werd 
gemeten (Hoofdstuk. VIII). De toename van de bloeddoorstroming in het 
striatum en de hersenstam kan het gevolg zijn van de talrijke opiaat 
receptoren, die :i.n deze gebieden voorkomen. Echter, een excitatoire 
input, waarschijnlijk vanuit het l~isch systeem, mag niet worden 
uitgesloten. Bet is mogelijk dat activatie van het sUbiculum via de 
enkefal.inerge banen, secundai.re epileptische foci kan induceren. Een 
onverwacht effect was de toename in de doorbloeding van het cerebellum. 
Dit gebied bezit weinig opiaat receptoren en alleen de perikarya van de 
Golgi cellen kunnen .. enkefalin-positief" worden genoemd. Bovendien 
ligt bet cerebellum ver van de laterale ventr1kels en is het dus niet 
waarschijnlijk dat bet erikefaline~ enkele minuten na toediening het 
cerebellum al heeft bereikt. 
dan kan een gelijkaardig 
Echter~ indien dit het geval zou zijn~ 
mechanisme zoaJ..s is geopperd voor de 
hippocampus, nL door disinhibi.tie~ ook hier van toepassing zijn 
aangezien bet cerebellum een relatief boge concentratie van GABA-erge 
neuronen en zenuwbanen heeft. oaarentegen kan ook een excitatoire 
input vanuit de hersenstam. en het ruggemerg de reden zijn van een 
verhoogde activiteit in het cerebellum. De resultaten wijzen echter op 
de noodzaak van verder onderzoek naar de relaties tussen enkefalinen en 
bet cerebellum~ vooral ook omdat uit klinisch onderzoek is gebleken dat 
er een sterke relatie bestaat tussen bet cerebellum en bepaa].de vormen 
van epilepsie, welke geassocieerd zijn met afname van de GABA 
concentrati.e in de cerebrospinale liquor. 
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samenvattend leiden de beschreven 
concl.usi.es: 
resultaten tot de volgende 
L Enkejatt..nen, tvt t.oeged1...end, beret.ken aLte deZ..en van he't 
ventr1...cu7.,atr sys'teem, me't Lnbegrtp van het centraat kanaat van 
he't ruggemerg en de e~racerebrate rut~e, btnnen 10 mtnuten. 
2. Actt..va'tte van 8 optaat recep~ren ts essentteet voor het 
on'ts'taan van optotd-getnduceerde epttepttsche verschtjnseten, 
'terr.JtJ•t acti.vat;:te van f.L opi.aat; recep'toren een an'ti.convuz.stef 
effect; heef't. 
3. ~ kOr'te tatent;tettjd van etectrograttsche pte~tvt'tett, na 
tvt; ~tentng van enkefaLtnen, suggereert he't bes'taan van een 
opt.ot.a convu.'Ls1...ef sys"teem t.n de a:&rect;e nalYi.J"he-Ld van ae 
Laterate ven~tkeLs. 
4. Dirt;. convu1si.ef sys'teem U,gt; r.,aarschi,jn"L"{.jk t.n de hi-ppocampus, 
meer spectjtek tn het subtcutum of in de pyramtdaLe ceLLaag 
van he~ ~1 geb~ea. Vanu~t a~t geb~ed kunnen exc~ta~~re 
banen topen naar andere hersengeb~eaen zoa1s de hersenstam en 
het: cerebe1tum. 
5. E:r bestaat een ste:rke correLat~e tussen neuronaLe ~~v~te~t, 
energ~everbru~k en aoorbLoea~ng van de versch~tLende 
hersengebt.eden. 
5. Bepaa1de narcot~serende stoffen kunnen een sttmuLerende 
u~toefenen op op~aat-get.nauceerae 
exct.tatteverscht.jnse1en. 
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